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Abstract 
 
The encapsulation and release of bioactive molecules from polymeric vehicles represents the 
holy grail of drug and growth factor delivery therapies, whereby sustained and controlled 
release is crucial in eliciting a positive therapeutic effect. To this end, electrospraying is 
rapidly emerging as a popular technology for the production of polymeric particles containing 
bioactive molecules. Compared with traditional emulsion fabrication techniques, 
electrospraying has the potential to reduce denaturation of protein drugs and affords tighter 
regulation over particle size distribution and morphology. In this article, we review the 
importance of the electrospraying parameters that enable reproducible tailoring of the 
particles‟ physical and in vitro drug release characteristics, along with discussion of existing 
in vivo data. Controlled morphology and monodispersity of particles can be achieved with 
electrospraying, with high encapsulation efficiencies and without unfavorable denaturation of 
bioactive molecules throughout the process. Finally, the combination of electrospraying 
with electrospun scaffolds, with an emphasis on tissue regeneration is reviewed, depicting a 
technique in its relative infancy but holding great promise for the future of regenerative 
medicine. 
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Abbreviations 
 
ALP, alkaline phosphatase; 
API, active pharmaceutical ingredient; 
AV, applied voltage; 
BDNF, brain-derived neurotrophic factor; 
BDP, beclomethasone dipropionate; 
BSA, bovine serum albumin; 
C6, coumarin-6; 
CD, circular dichroism; 
Cent, critical entanglement concentration; 
Chi, chitosan; 
CLSM, confocal laser scanning microscopy; 
Cov, critical chain overlap concentration; 
CS, chondroitin sulphate; 
DCM, dichloromethane; 
DDPS, drug delivery particulate systems; 
DMF, N,N-dimethylformamide; 
DMSO, dimethyl sulfoxide; 
DOX, doxorubicin; 
DSC, differential scanning calorimetry; 
DTAB, didodecyltrimethylammonium bromide; 
EBM-20, endothelial media; 
EE, encapsulation efficiency; 
EGF, epidermal growth factor; 
ELP, elastin-like polypeptides; 
FBS, fetal bovine serum; 
FDA, food and drug administration; 
FITC, fluorescein isothiocyanate; 
FR, flow rate; 
FTIR, Fourier transform infrared; 
GF, growth factor; 
H&E, hematoxylin and eosin; 
HA, hydroxyapatite; 
HUVEC, human umbilical vein endothelial; 
HyA, hyaluronic acid;  
ID, internal diameter; 
IGF-1, insulin-like growth factor-1; 
KOW, octanol/water partition coefficient; 
LC, loading capacity; 
LF, lung fibroblasts; 
Me, average entanglement molecular weight; 
MgCO3, magnesium carbonate; 
Mg(OH)2, magnesium hydroxide; 
MPHB, methylparahydroxybenzoate; 
MSC, mesenchymal stem cell; 
MW, molecular weight; 
MWD, molecular weight distribution; 
NGF, nerve growth factor; 
NHEF, human epidermal fibroblasts; 
NHEK, human epidermal keratinocytes; 
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o/o/w, oil-in-oil-in-water; 
PAAC, poly(amidoamines)-cholesterol;  
PCL, polycaprolactone; 
PDGF, platelet-derived growth factor; 
PEG, polyethylene glycol; 
PEO, polyethylene oxide; 
PEUU, poly(ester urethane) urea; 
PLA, polylactide; 
PLACL, poly(L-lactic acid)-co-polycaprolactone; 
PLGA, poly(lactic-co-glycolic acid); 
PLL, poly(ε-carbobenzoxy-L-lysine); 
PLLA, poly-L-lactide; 
PMMA, poly(methyl methacrylate); 
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PSU, polysulfone; 
PU, polyurethane; 
PUU, polyurethaneurea; 
PVA, poly(vinyl alcohol); 
PVC, poly(vinyl chloride); 
Rg, radius of gyration; 
RHOB, rhodamine B; 
RHOBOEP, rhodamine B octadecyl ester perchlorate; 
SD, standard deviation; 
SDS-PAGE, dodecyl sulphate-polyacrylamide gel electrophoresis; 
SEM, scanning electron microscopy; 
SMC, smooth muscle cell; 
SS, salbutamol-sulfate; 
TE, tissue engineering; 
TEC, tissue-engineered construct; 
TET, tetracycline hydrochloride; 
TFE, 2,2,2-trifluoroethanol; 
TGF- β1, transforming growth factor beta-1; 
TPP, tripolyphosphate; 
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UV, ultraviolet; 
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w/o, water-in-oil; 
w/o/w, water-in-oil-in-water; 
XPS, X-ray photoelectron spectroscopy; 
XRD, X-ray diffractometry. 
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1. Introduction 
 
The need for controlled delivery of therapeutic molecules has prompted the investigation 
of polymeric particles as biodegradable reservoirs which are designed to degrade at a 
determined rate, thereby releasing their encapsulated molecules for sustained and site-specific 
delivery [1-2]. This approach could potentially overcome the limitations of bolus delivery 
and has drawn much research attention in the last decades, particularly in the fields of cancer 
therapies, hormonal treatments, asthma delivery, and tissue engineering, for which tailored 
and multiple-molecule delivery is necessary for therapeutic effect [3]. Many techniques exist 
for producing these drug delivery particulate systems (DDPS) with emulsion/evaporation-
based methods being the most extensively used [4]. In this context, the term “drug” refers to 
any type of molecule that has a therapeutic effect. Coacervation, spray-drying, 
nanoprecipitation and microfluidics are additional techniques each presenting their own 
specific advantages and they are broadly described in the literature [5-8]. However, to date, 
very few of the DDPS generated using these techniques have been effectively translated to 
the clinic, with few devices being commercialized each year. This lack of translational 
research is mainly attributed to several shortfalls associated with these production methods 
[9]. For instance, there are issues surrounding molecule degradation (such as denaturation of 
proteins) and instability during the processes. In emulsion techniques, the aqueous/organic 
interface and shear stresses are the first source of limitation [10]. Moreover, entrapped 
molecules differ in terms of therapeutic function and physicochemical properties, 
demonstrating a different degree of stability and sensitivity to stress. In other techniques, 
prolonged exposure to organic solvents and residual traces of solvents or other processing 
agents in the final DDPS are of concern. Such factors can affect the nature and stability of the 
encapsulated therapeutic molecules, limiting their performance both in vitro and in vivo, and 
thus limiting their clinical use. Furthermore, different applications require different 
therapeutic molecule release profiles matching the need of a specific treated tissue, and 
ideally mimicking the in vivo release profiles generated by the cells from such tissues. For 
this to happen, it is critical to have a thorough grasp of the complex interplay of fabrication 
parameters which govern the resultant particle characteristics. Particle size and morphology 
for example ultimately dictate the degradation, and hence release profiles from DDPS, 
although it should be noted that tight control is currently limited in the traditional fabrication 
techniques.  
One approach to overcome these drawbacks is the technique of electrospraying. Although 
electrospraying is a well-established technique in the field of mass spectrometry and ink-jet 
printing, it has only been applied to the loading of therapeutic molecules in the last 20 years 
and its understanding and optimization are still in their relative infancy with respect to 
biological loading [11-13]. Briefly, in electrospraying, a high voltage is applied to a liquid 
infused through a capillary nozzle. The electric charge generated on the droplet competes 
with the surface tension of the droplet, causing the droplet to break up in nano- to micro-
droplets, which undergo solvent evaporation. The resulting dried particles can then be 
collected [14]. Therapeutic molecules can be incorporated into the polymer solution prior to 
electrospraying resulting in loaded particles. There are numerous advantages to 
electrospraying including the following: the use of an emulsion is optional but not required; 
there is no use of high temperature such as in spray-drying; there is no further drying step 
required since particles are instantaneously dried during the process; and there is an enhanced 
control over the size distribution of particles with the possibility of producing quasi-
monodisperse particles [15]. The latter is particularly desirable in drug delivery since 
monodispersity provides more controlled, and hence reproducible release profiles, which may 
in turn be more easily customized for a desired application [16]. Furthermore, in the specific 
case of nanoparticles, size affects cellular uptake and thus uncontrolled size distribution may 
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lead to different biological responses [17-18]. Control of size is thus of paramount 
importance when producing loaded polymeric particles and electrospraying is a technique 
which can provide such control over and above that achieved with traditional techniques, 
when appropriate parameters are used [19].  
Electrospraying also holds potential to reduce denaturation by limiting exposure to organic 
solvents and is highly versatile in terms of the choice of polymers, apparatus, and therapeutic 
molecules. For instance, if the therapeutic molecule is highly sensitive to solvents, such as 
enzymes and DNA molecules, coaxial electrospraying may be employed. In this way, core-
shell capsules are formed and the protein resides in the core of the capsule in an aqueous 
solution while the polymer matrix composes the shell of the capsule [20]. Finally, although 
electrospraying through one nozzle has a low throughput, the flexibility of the technique 
would enable the use of several nozzles in parallel for a multiplexed system, ideal for scale-
up [21-22]. To date, therapeutic molecules such as antibiotics (ampicillin [23], rifampicin 
[24]), anti-cancer agents (paclitaxel [25-32], doxorubicin [33], suramin [30], cisplatin [34]), 
inhalation drugs (beclomethasone dipropionate (BDP) [35], salbutamol-sulfate (SS) [36]), 
anti-inflammatory drugs (celecoxib [37], budesonide [38], naproxen [39]), drugs for 
hormonal treatments (β-oestradiol [40], tamoxifen [41-42]), model proteins (bovine serum 
albumin (BSA) [43-46]) and growth factors (insulin-like growth factor-1 (IGF-1) [47], 
vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [48]) 
have been loaded in electrosprayed particles and these studies will be discussed hereafter.  
Here we present a comprehensive review of the current state of the art in electrospraying 
technology for the controlled release of therapeutic molecules from polymeric particles. We 
review the methods used for producing electrosprayed particles and encapsulating therapeutic 
molecules, including important considerations to enable both the physical properties and in 
vitro drug release profiles of the particles to be tailored and optimized. The focus of the 
review is on in vitro data since very little in vivo data is available yet in the literature, 
although discussion of existing in vivo data is also provided. The various applications of 
electrospraying with electrospinning technologies, with an emphasis on tissue engineering, 
are also reviewed, for a portrayal of the latest techniques used to produce scaffolds in the 
diverse and fascinating field of regenerative medicine.  
 
2. The technique of electrospraying  
 
2.1. Electrospraying principles 
 
Electrospraying is a method of liquid atomization, also known as electrohydrodynamic 
atomization. The principle of electrospraying is based on the theory of charged droplets; 
stating that an electric field applied to a liquid droplet exiting a capillary is able to deform the 
interface of the droplet [12]. The electric charge generates an electrostatic force inside the 
droplet which competes with the surface tension of the droplet, forming the Taylor cone, 
characteristic of a charged droplet. Eventually, the electrostatic force, generated by the use of 
high voltage on the capillary, is able to overcome the surface tension of the droplet. The 
excess charge then needs to be dissipated and smaller charged droplets on the micro to nano-
scale are ejected from the primary droplet, thus reducing its charge without significantly 
reducing its mass. Due to Coulomb repulsion of the charges, the droplets disperse well and do 
not coalesce during their flight towards the collector [15]. Several spraying modes can occur 
during electrospraying; the most desired being the single cone-jet mode, due to its stability 
and reproducibility [14].  
The various theories of electrospraying physics have been summarized elsewhere with 
reviews on the recent advances and applications of the technology [11-12] however limited 
literature exists pertaining to theoretical and practical inclusion of bioactive molecules in this 
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process. Briefly, the two major parameters that characterize the electrosprayed aerosol are the 
size of droplets and electric charge. The latter is difficult to determine, due to parasitic 
electrical discharge, although the maximum surface charge of a droplet, q, has been identified 
as a function of the surface tension, γ, and radius of droplet, R, expressed in Equation (1) 
[49]. From the surface charge, the Rayleigh limit, LR, can be identified, which determines the 
charge leading to droplet break-up (fission) and is expressed in Equation (2) where ε is the 
permittivity of the surrounding medium. Droplets produced by electrospraying are highly 
charged, usually close to half of the Rayleigh limit [12].  
 
 
Similarly, the jet break-up mechanism is shown to be dependent on the ratio of the 
electrical normal stress over the surface tension stress. It is dependent on the viscosity and 
surface charge as in the Rayleigh limit (Equation (2)), but also on the acceleration of the jet. 
With increasing flow rate, the current increases and the stress ratio of the jet increases, above 
a threshold value whereby the jet starts to whip, leading to the production of heterogonous 
sized droplets. Ideally, a sufficient stress ratio value must be employed to allow for jet break-
up, but still a minimal value must be obtained for production of monodisperse and 
homogeneous particles [14]. 
 
2.2. Fabrication  techniques 
 
The electrospraying setup can be simple and cheap: a polymer solution is loaded into a 
syringe fitted with a conductive nozzle, and infused at a desired rate generally implemented 
by a syringe pump. The nozzle is subjected to high voltage (in the order of kilovolts and 
mostly positive) and various types of collectors, often grounded or more rarely negatively 
charged, are placed at a distance ranging from a few centimeters to several tens of 
centimeters from the nozzle. Once the droplets are ejected from the Taylor cone according to 
the theory of charged droplets, solvent evaporation leads to the progressive contraction and 
solidification of droplets resulting in solid polymeric particles impacting onto the collector. 
While particles are generally assumed to be dry or proven to contain residual solvent falling 
within the limit of safety standards [50], many studies also use subsequent vacuum treatment 
to ensure all residual solvent is removed. In the context of loading, the biologically active 
molecule (biomolecule) is generally mixed into the polymer solution before electrospraying; 
this approach is covered in section 2.2.2, Encapsulation of biomolecules.   
 
2.2.1. Electrospraying apparatus 
 
Electrospraying and drug loading characteristics can be tailored by changes in the choice 
and configuration of the equipment. One type of apparatus involves the use of nozzle-ring 
devices (Fig. 1A) which are placed inside glass chambers and subjected to a stream of 
air/nitrogen (Fig. 1B). This setup is sometimes referred as the “Delft type” (from the 
Technical University of Delft, The Netherlands) [32]. A potential difference is generated 
between the nozzle and a ring placed around the nozzle [27, 31-32, 43]. Usually the high 
voltage is applied on the nozzle and the lower voltage on the ring, respectively. The use of a 
ring stabilizes the electrospraying process [32], enabling better control over the desired 
spraying pattern [31]. For instance, in the single cone-jet mode, more uniform particles are 
produced [28]. The use of a ring is recommended when using water as the solvent since a 
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stable cone-jet mode is harder to achieve with water [33]. A corona discharge is generated by 
a grounded needle placed opposite the charged nozzle in order to discharge the highly 
charged droplets. Particles can be collected through filters, transported by an air/nitrogen 
flow applied in the chamber [31], or collected around the grounded needle in a Petri dish 
[43]. The use of a chamber reduces solvent evaporation rate and smaller particles may be 
produced [28], however, yield is lowered in this configuration due to deposition of particles 
in the glass wells of the chamber (where up to 30% can be deposited) before collection in the 
filter [31, 45]. Consequently, this setup is not recommended for loading of molecules where 
losses cannot be afforded. However it can be optimized by improving vacuum aspiration and 
efficient discharging of particles [31] to reach up to 80% yield. Furthermore, the reduction of 
solvent evaporation rate generated by using an enclosed chamber can lead to smoother 
microparticle morphologies due to enhanced polymer relaxation and thus better organization 
of polymer chains within the evaporating droplet [51], which, in turn, allow more 
homogenous particle degradation and release.   
An alternative method for collection involves electrospraying loaded droplets into a liquid, 
within a beaker containing an immersed grounded collector [44-45, 52] or a wire wrapped 
around the beaker [36] (Fig. 1C-D). Collection media include distilled water [44-45], ice-
water/methanol [53], anhydrous ethanol [30], or 70% ethanol supplemented with surfactants 
(such as 0.01% to 0.1% (v/v) Polysorbate 80 (Tween 80) [36]), to lower the surface tension 
of the solution and prevent the aggregation or coalescence of particles [7]. However, it should 
be noted that high surfactant concentrations (such as >0.1% of Tween 80) have been shown 
to broaden the size distribution of particles which reduces consistency between batches [36]. 
Stronger solvents such as acetone may also be used, in order to neutralize residual solvent 
from the spraying solution [52]. After collection in the liquid, particles can be further filtered 
and dried. The major disadvantage of this collection technique is the loss of surface-adsorbed 
drugs which may be desorbed into the media. There is, therefore, no burst release of 
biomolecules (from the surface of electrosprayed particles) seen with these systems, and a 
proportional amount of molecules is lost, which again is a concern for loading efficiency and 
cost. An alternative is to use a collection media in which the particles have poor solubility, as 
seen for polylactide (PLA) particles electrosprayed into 70% ethanol, preventing the leakage 
of the drug [36]. The use of additives in the collection media has also been utilized for cross-
linking of bovine serum albumin-loaded chitosan capsules electrosprayed into an aqueous 
tripolyphosphate solution, to improve the mechanical properties of capsules [44]. 
Agglomeration in solution is a potential issue with hydrophobic polymers when 
electrospraying in aqueous solutions. Coating is one approach to enable better stabilization of 
individual particles as seen for poly(lactic-co-glycolic acid) (PLGA) particles electrosprayed 
into a poly(vinyl alcohol) (PVA) solution [22].  
When solid matrices, such as hydrogels, have been used to entrap particles, as seen in 
cancer treatment where the containment of particles may be necessary, loaded electrosprayed 
microspheres could be electrosprayed for a second time, from an aqueous solution containing 
alginate, directly into a calcium chloride, CaCl2, solution. The instantaneous gelation resulted 
in calcium-cross-linked hydrogel macrobeads that held the microspheres within the matrix. 
Low voltages were used in this context so that the dripping mode of electrospraying occurred, 
generating macrobeads with millimeter sizes. This mode is usually unwanted when 
electrospraying nano/microparticles due to the macro-size outcome, but it does present an 
interesting alternative for generating larger particles such as hydrogel macrobeads that act as 
holding matrices. Again, the use of a surfactant such as Tween 80 in the alginate solution is 
recommended so that the highly hydrophobic microspheres stay uniformly suspended during 
dripping. According to gelation time, CaCl2 concentration and microsphere loading, different 
release kinetics may be obtained with this setup [25]. 
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The most common collector for electrospraying polymers solutions containing 
biomolecules remains a conductive and grounded collector such as an aluminum or copper 
substrate [23-24, 33, 35, 51] (Fig. 1E). The use of a conductive substrate restricts the 
deposition of particles to the charged area, limiting losses and does not require any 
subsequent washing or filtering step.  
In practice, despite electrospraying enabling better control over size and morphology of 
particles compared to the traditional fabrication techniques, it is not without associated 
drawbacks, including the low-throughput of the technique and yields in the order of 
milligrams/hour [12]. This can be overcome with multiple electrospray sources   as seen in 
Fig. 1E. An extractor is essential in this type of setup to minimize interference between 
sources and to localize the electric field. Morphology and size of microparticles were similar 
to that of the single setup and particle production could be increased from milligrams to 
grams per hour using 19 parallel nozzles [21].   
 
 
 
Fig. 1. Electrospraying apparatus. (A) Formation of the Taylor cone in a nozzle-ring setup. (B) 
Electrospraying via a nozzle-ring setup inside a glass chamber under air flow [32]. (C,D) 
Coaxial electrospraying in a solution with size measurement by laser optical spectrometer 
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[52]. (E) Single and multiplexed electrospray setup on grounded collectors [21]. Adapted 
from [21, 32, 52] with permission. 2006, 2010 Elsevier Science Ltd. [21, 32]; 2006 Royal 
Society [52]. 
 
2.2.2. Encapsulation of biomolecules 
 
Conventional medication via oral or bolus administration typically does not provide 
spatially or temporally controlled release of therapeutic molecules. The short half-lives in 
solution of most of these molecules also imply that they lose their bioactivity quickly 
following implantation, or are rapidly cleared by metabolism in the body [9]. Such shortfalls 
require high doses of therapeutic molecules to be used, resulting in increased cost and 
possible complications due to levels potentially toxic for cells and tissues [54].  
In recent years, the encapsulation of therapeutic molecules has become a powerful tool for 
delivering controlled amounts to target cell populations and tissue sites, with minimal signal 
propagation to non-targeted cells and tissues. Encapsulation can be obtained by the 
processing of biodegradable polymers which maintain integrity and relative long-term 
biological activity of therapeutic molecules. Polymeric devices can finally provide an 
exposure for extended periods ranging from hours to months by gradual polymer degradation 
allowing a specific release pattern of biomolecules for treatment [55]. 
Several methods can be employed for the encapsulation of biomolecules (also referred as 
drugs) into electrosprayed polymeric particles, as shown in Fig. 2. The resultant particles may 
be categorized into two distinct groups: 
- Particulate systems, where the drug is intimately distributed within the polymer structure; 
- Capsules, where the shell is made of the polymer while the aqueous drug solution is 
located in the core. 
Capsules may be obtained by coaxial electrospraying shown in Fig. 2 RHS, where the 
aqueous core solution and organic shell solution are extruded independently through two 
concentric nozzles leading to the electrospraying of particles with a distinct core-shell 
structure. The bi-component syringe may be connected via tubing to separate syringes with 
independent flow using two syringe pumps [12, 20].  
Particulate systems may be obtained by monoaxial electrospraying where the drug is 
mixed with the polymer solution before electrospraying commences, shown in Fig. 2 LHS. In 
the course of electrospraying the solvent evaporates from the droplet and the drug remains 
entrapped within the polymer structure, ideally randomly distributed. The drug can be mixed 
in its solid state, where it is directly dispersed in the polymer solution and vortexed before 
electrospraying. The drug may also be dissolved in an aqueous solution before mixing with 
the polymer solution, by emulsification or nanoprecipitation as shown in Fig. 2. Emulsions 
are widely used in traditional encapsulation methods with the water-in-oil-in-water (w/o/w) 
double emulsion being the most common used, since it provides access to a wide range of 
particle sizes by adjusting the conditions of the process. For electrospraying, a single water-
in-oil emulsion (w/o) may be performed where hydrophilic molecules are first dissolved in 
water before encapsulation. Different surfactants may be added to tailor the encapsulation 
efficiency (EE) and release profiles [43]. However, the interface between the organic and 
aqueous phases may result in protein denaturation and aggregation, which is the main 
drawback of all emulsion-based methods [10, 51]. Nanoprecipitation, on the other hand, 
avoids the denaturation problem since high shearing rates and interfaces are absent. However 
it can lead to agglomeration and is not suitable for hydrophilic biomolecules due to leakage in 
the aqueous phase [8]. Solid dispersion may thus remain the most attractive option in 
monoaxial electrospraying, with no or limited denaturation and high versatility of drugs that 
may be incorporated (both hydrophilic and hydrophobic, small molecule and protein drug 
types). 
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Advantages of coaxial electrospraying include high drug encapsulation efficiencies within 
the capsules and the assurance that the drug has minimum contact with the organic solvent 
from the polymer solution, meaning less risk of drug degradation. Nevertheless, the 
biomolecules remain in aqueous solution within the capsules before delivery, which happen 
when the shell starts to degrade and channels open for release. This is an issue since the 
stability of some biomolecules in the aqueous state is known to be lower compared to its dry 
state, which may consequently result in loss of bioactivity [43]. Nevertheless coaxial 
electrospraying supposedly allows better control over release kinetics due to an increased 
number of variable parameters [20, 56-57]. 
More complex devices such as tri-needle coaxial devices can allow for more drugs to be 
loaded within separated layers of the capsule for sequential and multiple release [53, 58]. 
This can also be achieved with normal coaxial electrospraying with loading of a second drug 
in the polymer core. However it was previously shown that the hydrophilic nature of the drug 
is of importance and capsules that contain a hydrophobic drug in the core and a hydrophilic 
drug in the shell can easily be made, whereas the opposite configuration is more difficult to 
achieve [30].  
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Fig. 2. Different methods of drug incorporation within polymeric particles through monoaxial 
electrospraying (by aqueous nanoprecipitation, emulsification, and solid dispersion) for 
production of particulate systems (LHS), and coaxial electrospraying for production of 
capsule systems (RHS), respectively.  
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3. Control of particle characteristics with electrospraying parameters 
 
3.1. Importance of electrospraying parameters 
 
Although electrospraying is accepted as a technique which can produce particles with 
monodisperse size distributions and reproducible morphologies by controlling the 
electrospraying parameters [21, 59], producing particles with very specific requirements 
remains challenging due to the large number of variables involved in the process and their 
complex inter-dependence. The primary pre-requisite for reproducible electrospraying and 
monodisperse size production is the stable cone-jet mode, for which the working window can 
be found by tailoring the field strength, conductivity and flow rate of the polymer solution. 
Morphology and size can be further controlled by adjusting additional parameters, such as the 
polymer concentration and molecular weight, the solvent vapor pressure, the flow rate, the 
electrospraying distance and chamber environment. 
 
3.1.1. Polymers 
 
3.1.1.1. Polymer types  
Currently, the most common synthetic biodegradable polymer used in the field of drug 
delivery and also most commonly used in electrospraying is poly(lactic-co-glycolic acid) 
(PLGA). This aliphatic polyester is approved by the food and drug administration (FDA) and 
it is widely used in several medical devices (sutures, grafts, prostheses) and drug delivery 
devices [55]. PLGA degrades mainly through hydrolysis, which distinguishes it from natural 
biodegradable materials such as fibrin and collagen which are actively degraded 
enzymatically in the presence of cells. The natural products arising from degradation (lactic 
and glycolic acid) are then cleared by metabolic pathways [60]. In contrast, the degradation of 
PLGA via hydrolysis results in the generation of acidic species which can provoke 
inflammation of tissues and generate problems for long-term stability when encapsulating 
bioactive molecules. For instance, in vitro simulations of the polymer microclimate of PLGA 
microparticles produced using traditional methods revealed a highly acidic environment 
(pH<3), further triggering unfolding of encapsulated bovine serum albumin, resulting in 
peptide bond hydrolysis and non-covalent aggregation [61]. Anti-acid excipients such as 
magnesium carbonate (MgCO3) or magnesium hydroxide (Mg(OH)2) can be used in the 
microparticle fabrication process to buffer the pH [62]. BSA structural losses and aggregation 
were indeed prevented for over one month with Mg(OH)2 from PLGA microparticles and this 
strategy was further employed for delivering angiogenic basic fibroblast growth factor and 
bone-regenerating morphogenetic protein-2 [61]. However no studies so far have tested these 
anti-acids in electrosprayed particles, where microclimate pH was mentioned but not 
addressed [43], although PLGA remains the most utilized polymer for electrosprayed particles 
[24-31, 43]. 
Polylactides (PLAs) have similar properties to PLGAs but they afford a more crystalline 
structure responsible for a slower degradation [30]. Select studies have chosen pure PLAs 
over the PLGA copolymers for monoaxially electrosprayed particles [32, 36, 45-46], or 
simultaneously in coaxial electrospraying with PLA as the core and PLGA as the shell to 
ensure that the drug in the core was not released prematurely by choosing a core of slower 
degrading material than the shell [30, 63]. Very different molecular weights (MW), such as 2 
kDa [36] and 175 kDa [45], have been chosen when electrospraying PLAs. MW has a great 
influence on degradation and thus subsequent release of encapsulated biomolecules; PLA 2 
kDa degrades quicker in vivo and is more soluble than higher MW PLAs [36]. 
The biodegradable polyester polycaprolactone (PCL) is an interesting candidate for drug 
delivery and has also been used in electrospraying [27, 31, 38, 40, 43]. Compared to PLGA 
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and PLA, PCL is semi-crystalline with a melting temperature of approximately 60°C and a 
glass transition temperature around -60°C (compared to 40 to 65°C for PLGA/PLA) 
conferring superior viscoelastic properties and easy formability [64-65]. PCL is also FDA-
approved and various drugs have been encapsulated in PCL microspheres and nanospheres 
since PCL is highly permeable to small drug molecules. Due to its crystallinity and lower 
ester concentration, PCL presents the advantage of a less acidic environment being generated 
during degradation as compared to PLGA-based polymers [40, 66]. Nevertheless, the high 
hydrophobicity of PCL remains a concern for encapsulation of hydrophilic substances such as 
peptides, enzymes and other proteins [2].   
Although all the aforementioned biodegradable polyesters, PLGA, PLA and PCL, have 
generated considerable interest in the last decades as potential matrices for drug delivery, 
overall concerns remain, particularly with regard to slow degradation and hydrophobicity (in 
the case of PCL) and acidic environment generation (in the case of PLGA and PLA) leading 
to possible instability, aggregation and structural changes of the loaded drug/protein. The 
introduction of functional groups can provide these polymers with tunable crystallinity and 
enhanced hydrophilicity. The description of such functional polymers and use so far in the 
field of drug delivery has been recently summarized in the review by the group of Hennink 
[67]. 
An elegant approach to improve the utility of PCL is to copolymerize with a more 
hydrophilic commoner. For example, PCL has been functionalized with hydrophilic 
components such as polyamino ethyl ethylene phosphate (PPE-EA), in order to improve 
hydrophobicity. The amphiphilic block copolymer, PCL-PPE-EA, was indeed shown to 
encapsulate BSA more efficiently than PCL alone [68]. During the w/o emulsion procedure, 
when the protein is introduced into the polymer solution, micelles are formed around the 
protein with the hydrophilic part of the polymer (PPE-EA) in contact with the protein. Such 
micelle-derived electrosprayed particles encapsulating BSA were 3 µm in diameter on 
average and exhibited a linear release profile for 20 days whereas no protein was released 
from PCL only particles. Unfortunately, the formulation and processing parameters of PCL 
particles loaded with BSA were not described in the study and the release data was not 
normalized to the amount of loaded protein, rendering the assessment of the system delicate 
[68]. 
Natural polymers have also been electrosprayed, including elastin-like polypeptides (ELP) 
[33, 69], a bioresponsive biopolymer that can be dissolved in water, an advantage compared 
to polyester based polymers that require organic solvents to dissolve them. ELP are inspired 
by the amino acid sequence of natural elastin and can be synthesized by recombinant DNA 
methods, allowing for a control over the ELP sequence and thus over its biofunctionality [70]. 
Chitosan is another natural polymer that has been electrosprayed in the past. Chitosan comes 
from the alkaline deacetylation of chitin and its main advantage is that it is hydrophilic, which 
improves facilitation of drug-polymer interactions compared to hydrophobic synthetic 
polymers [44]. Its performance as a drug delivery system is affected mainly by its molecular 
weight and degree of deacetylation, while its cationic nature allows for ionic cross-linking for 
improved material properties [23, 44]. Compared to synthetic polymers, the degradation 
products of chitosan are amino sugars, which are easily metabolized by the body [23], 
therefore there is no concern of an acidic microclimate being generated by chitosan particles. 
So far, the use of chitosan in electrospraying has been used limited to the use of encapsulating 
BSA [44], ampicillin [23], an antibiotic to treat bacterial infections, doxorubicin [71], an anti-
cancer agent, and insulin [72]. In the case of BSA and doxorubicin, the microparticles were 
sprayed in a tripolyphosphate (TPP) solution, a non-toxic biocompatible cross-linking agent 
ideal for chitosan [44, 71]. 
Miscellaneous polymers that have also seen use in electrospraying applications include 
poly(amidoamines)-cholesterol (PAAC) conjugates, for encapsulation of Tamoxifen [42]. 
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Along with their amphiphilic character – due to the presence of cholesterol, and low 
molecular weight  (13 kg/mol), they are likely to produce nanosized particles with a low 
degree of polymer chain entanglements, thus providing rapid drug release rates (within 
hours). Polyvinylpyrrolidone, a water soluble polymer, has also been used for self-assembly 
of nanoparticles including tristearin, a lipophilic excipient and naproxen, an anti-
inflammatory drug [39]. Although the versatility of electrospraying allows the use of many 
types of polymers, only a restricted number of polymers have been tested so far for 
encapsulation of biomolecules. Many more polymers remain to be investigated, for providing 
a higher degree of diversity in terms of physical and drug release characteristics of particles, 
as well as possibly enhanced drug-polymer interactions. 
 
3.1.1.2. Solvents 
Organic solvents are required to solubilize polymers prior to electrospraying. The most 
widely used solvent for electrospraying particles loaded with drugs is dichloromethane 
(DCM), a chlorohydrocarbon with the lowest boiling temperature (40°C) of the common 
solvents used in electrospraying. Other solvents include (by increasing boiling temperatures): 
acetone [46], chloroform [24], ethanol [36], acetonitrile [27], 1,2-dichloroethane [45-46], 
acetic acid [23, 44], and N,N-dimethylformamide (DMF) [46], which may be used alone or in 
combination. The boiling temperature of a solvent is the temperature at which the vapor 
pressure equals the ambient atmospheric pressure and it is representative of the solvent‟s 
volatility. Solvents with low vapor pressure (high boiling temperatures) are vaporized less 
easily than solvents with high vapor pressure (low boiling temperatures) and are thus less 
volatile.  
This means that polymer diffusion is reduced in electrosprayed droplets from solvents with 
high vapor pressures, where solvent evaporation occurs at a higher rate. This effects the size 
and morphology of particles and it was previously shown that an increase in boiling point, 
corresponding to a decrease in volatility, correlated with a decrease in particle size with 
smoother surfaces generated for solvents with boiling temperatures above 140°C (such as 
DMF, 146°C) [73]. A greater particle size and more textured surfaces can be seen with 
solvents with low boiling temperatures such as chloroform (61°C) [59] and dichloromethane 
(40°C) [74]. This is due to fast solvent evaporation, where less time is available for polymer 
chains to contract and re-arrange within the evaporating droplet exposed to electric field. 
Faster evaporation can also result in the formation of pores [70] and even hollow particles 
[32, 75].  
Importantly it was shown that a decrease in vapor pressure weakens the forces of polymer 
chain entanglements [76]. Therefore, the Coulombic repulsion is able to overcome the surface 
tension of evaporating droplets, leading to the ejection of small and highly charged offspring 
droplets. This was seen with PLGA particles where the addition of 30% DMF to chloroform 
reduced the vapor pressure from 21 kPa to 15 kPa and induced a bimodal size distribution. 
The use of a co-solvent with low vapor pressure is thus not recommended to obtain 
monodisperse particles [76].  
It must also be noted that different polymers have different interactions with solvents, 
affecting polymer chain entanglements and final morphology of particles and both 
concentration and molecular weight greatly dictate these interactions [77].  
 
3.1.1.3. Polymer solutions  
When electrospraying polymer solutions, electrosprayed droplets undergo solvent 
evaporation and polymer diffusion simultaneously. Chain entanglements occur during these 
processes and are responsible for the final morphology of particles. In electrospraying, 
uniform microparticles and smaller droplets are favored by limiting chain entanglements [78]. 
The number of entanglements per chain in solution, (ne)sol, can be expressed with the polymer 
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volume fraction φ, the average molecular weight Mw and the average entanglement molecular 
weight Me according to Equation (3): 
 
It was previously shown that electrospraying occurred for 1 entanglement per chain ((ne)sol 
= 2) whereas 2.5 entanglements per polymer chain ((ne)sol = 3.5) would lead to formation of 
fibers; a process known as electrospinning [78]. Beaded fibers can form for intermediate 
values of (ne)sol. Me is primarily a function of chain geometry and corresponds to the average 
molecular weight between entanglement junctions. Me is readily available for more than 70 
polymers but in the absence of experimental values, it can be theoretically estimated by 
employing the entanglement constraint model used by Shenoy et al. [78]. 
Polymer concentration plays an important role in the entanglement regime which dictates 
particle or fiber formation and is an essential parameter to control in order to optimize the 
process. The critical chain overlap concentration, Cov, is known as the point when solution 
concentration is equal to the concentration inside the radius of gyration of every single 
macromolecular chain and is inversely proportional to the intrinsic viscosity [η], as shown in 
Equation (4) [79]: 
 
 
When the concentration C is below Cov, there are no chain entanglements and the regime is 
known as the dilute regime (Fig. 3A). Above Cov, the concentration is large enough for chains 
to overlap but not sufficient to generate a significant degree of entanglement. The regime is 
the semi-dilute unentangled regime, and some entanglement is observed (Fig. 3B) although 
not desirable since particles have the ability to deform during evaporation, leading to inferior, 
non-reproducible morphology. Such a regime can be used for the production of 
electrosprayed films, another type of delivery device useful in some therapies such as 
chemotherapy. Multi layers of polymers encapsulating various drugs can thus be made by 
electrospraying in either the dilute or semi-dilute unentangled regime, allowing for a 
controlled release of therapeutic molecules tailored by the thickness of the films [29]. 
For electrospraying of particles, the regime of choice is the semi-dilute moderately 
entangled regime. It happens for Cent, the crossover from the semi-dilute unentangled regime 
to the semi-dilute moderately entangled regime, where a significant degree of entanglement is 
observed and dense, solid and reproducible particles can be produced (Fig. 3C). However for 
C/Cov>3, molecular cohesion is generally too high for electrospraying and beaded fibers or 
fibers are electrospun, corresponding to the semi-dilute highly entangled regime (Fig. 3D). 
For optimal particle electrospraying, it is thus essential to work above Cent but not overcome 
C/Cov>3. The molecular weight (MW) and molecular weight distribution (MWD) do affect 
Cov due to differences in intrinsic viscosity, and it was demonstrated that an increase in MW 
reduces the C/Cov ratio, narrowing the working window of the semi-dilute moderately 
entangled regime, thus narrowing the range of appropriate concentrations for reproducible 
electrospraying. On the other hand, for broader MWD, the ratio C/Cov required to obtain the 
semi-dilute highly entangled regime was shown to be higher than 3, broadening the working 
window of the semi-dilute moderately entangled regime where reproducible electrospraying 
can be obtained [79]. 
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Fig. 3. Left column: Physical representation at the molecular level of various entanglement regimes 
obtained for different polymer concentrations. Rg is referred as the radius of gyration). 
Adapted from [79] with permission. 2005 Elsevier Science Ltd. Right column: Examples of 
corresponding scanning electron micrographs of dried PCL microparticles. PCL 
concentration in chloroform was: (A) 5%, (B) 7.4%, (C) 8.7%, (D) 9.6% w/v. 
Electrospraying conditions were 26 G for needle gauge, 20-25 cm for tip-to-collector 
distance, 0.5 mL/h for flow rate and 10 kV for voltage. The molecular weight of PCL on 
average was 130 kg/mol with a polydispersity index of 1.45. Scale bar is 10 µm. 
 
3.1.2. Processing parameters 
 
3.1.2.1. Spraying modes 
Different spraying modes can take place in the course of electrospraying and they vary 
according to the field strength and flow rate of the polymer solution. The magnitude of the 
field strength is a key to reproducible spraying patterns [31] and its variation leads to different 
spraying modes, starting from the dripping mode and moving to cone-jet modes with 
increasing applied voltage [12]. When sufficient voltage is applied to the droplet to form the 
Polymer chain
Rg
(A) Dilute regime C < Cov
(B) Semi-dilute unentangled regime Cov < C < Cent
(C) Semi-dilute moderately entangled regime Cent < C < 3Cov
(D) Semi-dilute highly entangled regime C > 3Cov
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Taylor cone (corresponding to the change-over from dripping to cone-jet modes), the ejection 
of small and highly charged droplets assumes the form of a cone which proportionally 
increases with an increase in the tip-to-collector distance. This single cone-jet mode seen for 
moderate field strengths is stable and fairly consistent from one replicate to the next [40]. 
Conversely, when increasing the field strengths, multiple cone-jets are formed, which are 
unstable and unpredictable, and importantly can vary throughout the course of electrospraying 
[31]. Such modes can be found in all types of electrospraying setups and are also observed for 
the nozzle-ring setup when increasing the potential difference between the nozzle and ring 
[27]. The multiple cone-jet mode needs to be avoided so that only targeted areas are sprayed, 
in order to ensure a high yield of particles. This is especially important when loading 
expensive molecules, where minimal loss is desired.  
One strategy to obtain the single cone-jet mode is to lower the electrical conductivity and 
surface tension of the solution [40]. When incorporating therapeutic molecules to the polymer 
solution, the stable mode can be maintained by decreasing the protein concentration and the 
loading since the electrical conductivity increases with increasing protein concentration, as 
has been shown for BSA [46, 80]. As a result, the stable single cone-jet mode region shrinks 
and shifts to a lower flow rate for higher protein concentration (Fig. 4A-B). On the other 
hand, increasing the viscosity of solutions (by increasing polymer concentration for instance) 
results in a shift of the cone-jet mode to higher voltages, as seen in Fig. 4C. This is because of 
the lower conductivity of more viscous solutions: a stronger electric field should be applied to 
overcome the surface tension and liquid viscosity to form the cone-jet [40]. 
It is very important to keep in mind that only in the stable cone-jet mode is the production 
of monodisperse particles possible. Only then can the size and morphology of particles be 
controlled by carefully changing other parameters.  
 
 
 
Fig. 4. Mode selections maps to obtain different electrospraying modes, for (A) 5.5 mg/mL and (B) 
20 mg/mL as-prepared BSA solution. In the case of an unstable jet, a clear mode 
classification was not possible. Microdripping and spindle both refer to undesirable 
electrospraying modes [80]. (C) Cone-jet mode maps for different PCL solutions [40].  
Adapted from [40, 80] with permission. 2005 Springer [80]; 2010 Royal Society [40]. 
 
3.1.2.2. Electrical conductivity 
Since electrospraying depends on the electrostatic attraction of charged particles to a 
grounded or oppositely charged collector, the electrical conductivity, K, of the polymer and 
solvent is an important parameter when optimizing the process. Along with flow rate, 
electrical conductivity provides a powerful means to control the electrosprayed particle size, 
as demonstrated by the scaling laws from Gañan-Calvo, where a higher conductivity leads to 
a decrease in size [81].  
An increased conductivity of a solution implies that more charge is carried by the 
electrospraying jet. In general, a low electrical conductivity is preferred to obtain quasi-
monodisperse particles [76] since a higher conductivity may favor elongated particles or even 
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fibers if the polymer concentration is high enough [82]. Correlating with viscosity, stable 
electrospraying is known to be achieved only when viscosity is high or conductivity is low 
[83]. Changes in electrical conductivity can be obtained by changing the electrospraying 
solvent or using co-solvents, although this latter case may be detrimental to size distribution 
and morphology of particles [46, 76]. Organic solvents are generally less conductive than 
aqueous solvents and their conductivity can be increased by the addition of electrolytes, such 
didodecyltrimethylammonium bromide (DTAB) [28] or ammonium hydroxide [36], which 
can increase conductivity by orders of magnitude. For instance the conductivity of a 5% (w/v) 
PLGA solution in acetonitrile containing 10% (w/w) paclitaxel was shown to increase from 
0.51 μS/cm to 116.5 μS/cm by the addition of 2 mM DTAB. This led to a particle size 
decrease from around 1.2 μm to 355 nm [28]. Compared to pure solvents, it must be kept in 
mind that the addition of a polymer will most likely decrease the electrical conductivity, 
although remaining in the same order of magnitude [84].  
When the electrical conductivity of the solution is lower than 0.01 µS/m, it is likely that 
insufficient current can flow, and the liquid cannot be electrosprayed, although too a high 
conductivity value leads to unstable electrospraying [31]. The bending instability of the jet 
becomes more important when more charges are present due to increased conductivity, 
leading to a wider deposition of particles on the collector. With higher electrical conductivity, 
the Coulombic repulsion forces are higher and compete with the viscoelastic forces of the 
solution, disentangling more easily the polymer network which is being formed during 
electrospraying. In other words, increasing conductivity makes it easier for the solution to be 
broken up into smaller droplets. Therefore for the same polymer dissolved at the same 
concentration in a higher conductive solvent (or the same solvent but supplemented with 
organic salts), less chain entanglements take place during electrospraying, in turn reducing the 
final particle size. However, if the Coulombic repulsion forces are sufficiently high to 
overcome the entanglement forces, then Coulomb fission occurs before strong entanglements 
can form, and smaller offsprings are ejected from the primary droplet. This will provide a 
bimodal size distribution, with particles presenting various types of morphologies, mostly 
unwanted and further discussed in the section 3.2. Low electrical conductivity may thus be 
more favorable for electrospraying of quasi-monodispere microparticles.  
When nanoparticles are required, increasing conductivity may be a good means of 
reducing particle size, although sufficient viscosity needs to be ensured so that entanglement 
forces remain higher than Coulomb forces, and the ejection of offspring droplets is avoided. 
Higher flow rates can also be used to produce nanoparticles if higher salt concentration is 
used to increase solution conductivity [28]. In the context of electrospraying emulsions, the 
organic/aqueous volume ratio is another significant factor influencing the electrical 
conductivity whereby addition of water to the organic phase significantly increases the 
electrical conductivity of the resulting emulsions [45].  
 
3.1.2.3. Flow rate 
After the selection of polymer solutions, flow rate is arguably the second most important 
parameter in electrospraying and together with the solution parameters (polymer MW, 
concentration, solvent, and conductivity) can control polymer entanglements and Coulomb 
fission [21]. Flow rate thus has consequences for both the morphology and size of particles 
and must be judiciously chosen since both these characteristics will influence the drug 
dispersion within the polymer matrix, ultimately affecting drug release.  
Firstly, it is essential to use a flow rate that allows for complete solvent evaporation, which 
is not possible with high flow rates. Particles are partially solvated when they impact the 
collector leading to a deformed and non-consistent morphology [27, 59]. Furthermore, higher 
flow rates can trigger the formation of secondary and satellite droplets that confer a bimodal 
or polydisperse character to the size of electrosprayed particles. This is explained by the 
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processes involved in solvent evaporation from the charged droplet, based on φRay, the 
polymer volume fraction in a droplet at the Rayleigh limit, and expressed in Equation (5). Q is 
the liquid flow rate (m
3
.s
-1
), I the current, εair the permittivity of air, γ the surface tension of 
solution in ambient air, and d the initial droplet diameter. I/Q and d can be determined as a 
function of Q and the polymer solution properties. 
 
 
Considering φent as the critical entanglement polymer volume fraction and φov as the 
critical chain overlap polymer volume fraction, it was shown by Almería et al. that for 
φov<φRay<φent in the semi-dilute unentangled regime mentioned previously, the polymer 
network can preserve some droplet integrity, but is not strong enough to preserve the particle 
from deforming via stretching during the fission process, while droplets are stabilized from 
such rupture when φRay>φent [21]. For φRay<φov, the droplets behave like a pure liquid and 
there are no entanglements, leading to the ejection of offspring droplets from the primary 
droplet; a consequence of Coulomb fission. In order to obtain a spherical morphology and 
monodispersity, it is important that sufficient entanglements are present before the Rayleigh 
limit is reached so that the droplet cannot be disrupted by Coulomb fission, ensuring that 
φRay>φent. According to Equation (5), flow rate has a significant influence on φRay and it was 
shown for the morphology of PLGA particles that larger flow rates lead to smaller φRay, and 
thus non-spherical morphology and formation of satellite and primary droplets, while higher 
polymer concentrations would preserve particle sphericity at higher flow rates [21].  
In practice, the formation of satellite and primary droplets can be explained by the 
phenomena occurring when the droplets are ejected from the Taylor cone. Initially, a filament 
unites 2 droplets, but it is further broken up by the charge. Once broken from the farthest 
droplet, the filament flows back to the nearest droplet from the cone, and monodisperse 
particles can be achieved. This is seen for relatively low flow rates enabling φRay>φent. At 
increased rates, φRay becomes smaller, eventually falling in the case where φov<φRay<φent 
where entanglements are not strong enough to preserve the droplet integrity. Thus the 
filament cannot reach the former droplet anymore and instead it breaks, forming a secondary 
smaller droplet. At even higher flow rates, a filament between primary and secondary can 
form, which, being unable to reach back to the primary droplet, turns into a satellite droplet 
(even smaller than secondary droplets) [14]. If the solvent has a high evaporation rate, it is 
even possible that the filament remains frozen, leading not only to polydisperse sizes but also 
leading to elongated particles [21].  
The same rules apply for coaxial electrospraying where the inner and outer flow rates may 
strongly affect the properties of electrosprayed capsules. Usually the flow rate of the core 
solution is much lower than the shell solution [51], resulting in uniform sizes. In contrast, for 
a shell flow rate slower or equal to that of the core flow rate, irregular morphologies are 
obtained, while for increasing ratios of shell:core flow rates, the shell becomes thicker  [56]. 
This presents a useful tool for the tailoring of release kinetics. 
 
3.1.2.4. Other parameters  
Effect of gauge 
The diameter of a needle is commonly expressed in gauge (G), each gauge size arbitrarily 
correlating to multiples of 0.001 inches [85]. For the electrospraying of particles loaded with 
bioactive molecules, these diameters range from 18 G (internal diameter (ID) of 1.27 mm) 
[45-46] to 29 G (ID of 0.33 mm) [28]. Prior to electrospraying, beveled needles are typically 
shortened and given a flat end for homogeneous spraying, although characterization of the 
needle tip, while important, is often overlooked. The effect of gauge has little effect on 
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morphology or size of particles. For instance when comparing the size of PCL particles made 
with 21 G versus 26 G, the average size was equivalent for both gauges, however the size 
distribution was slightly broader for the bigger gauge (21 G) with standard deviation (SD) of 
3.42 while SD was 2.40 for 26 G, suggesting that a smaller gauge can produce a narrower size 
distribution [59]. A similar result was observed in the 20 to 26 G range when electrospraying 
ampicillin-loaded chitosan nanoparticles, where the use of the 20 G led to sputtering only, 22 
G led to a mixture of particles and sputtering, while 24 and 26 G led to spherical particles 
with no sputtering and with reduced polydispersity for the smallest gauge (26 G) [23].  
Effect of voltage 
The main incidence of voltage is on spraying modes as described previously in section 
3.1.2.2, Spraying modes. Within the single cone-jet mode, size is not significantly affected by 
voltage where only a slight decrease in size is observed when voltage is increased  [24]. 
Morphology however will be changed as stated by Shenoy et al., since as the voltage is 
increased, the morphology changes from spherical particles to elongated particles or beaded 
fibers to eventually only fibers if concentration is sufficiently high [78]. This is due to more 
charge acting on droplets with increased voltage, leading to stretching and elongation of 
droplets. It is therefore recommended to use moderate voltages that allow for the single cone-
jet mode to take place while maintaining the spherical morphology of particles.  
Effect of tip-to-collector (TTC) distance 
The lower limit of distance is determined by electric discharge. A small TTC distance can 
impair full solvent evaporation and consequently, wet microspheres impact the collector, 
leading to collapsing, coalescence and broad size distributions [23]. Increasing the distance 
leads to more spherical morphologies since polymer chains have sufficient time to diffuse 
within the droplet [59] and thus also reduced polydispersity. At constant voltage, a decrease in 
the TTC distance leads to an increase in the strength of the electric field, thus leading to a 
decrease in particle size [84]. Depending on the type of solvent used, an increase in TTC 
distance may also be detrimental for morphology as shown with polyacrylonitrile 
microspheres in DMF where at 10 cm, the evaporation rate of DMF allowed round spheres to 
be formed, while at 20 cm, the round spheres collapsed into half-hollow spheres and the 
authors stated that the evaporation rate was excessive. However this result was not clearly 
evident in the images shown by the authors, and no explanation was proposed [86].  
 
3.2. Tailoring of electrosprayed particle characteristics 
 
3.2.1. Morphology 
 
The morphology of electrosprayed particles is controlled by solvent evaporation and 
polymer diffusion [21]. The polymer solution thus plays a determinant role in these 
mechanisms, where the nature of polymer (solubility, molecular weight, concentration) and 
solvent (vapor pressure, miscibility, conductivity of solution) coupled with the solution flow 
rate form the levers of morphology tailoring [59]. As explained previously in the section 
3.1.1.3, regarding polymer solutions, concentration and molecular weight can dictate the 
entanglement regime taking place, leading to reproducible and solid electrosprayed particles, 
when a certain degree of chain entanglement is obtained. Therefore in most studies, 
morphology is initially linked to polymer concentration and molecular weight, where a 
decrease in concentration or an increase in molecular weight induces non-spherical 
morphologies such as shell-like, wrinkled, hollow particles, beaded fibers or particles with 
tails (Fig. 5A-B). 
As seen in the section 3.1.2, flow rate also has a significant influence on morphology 
through φRay, the polymer volume fraction in a droplet at the Rayleigh limit (expressed in 
Equation (5)), where it was shown that φRay needs to be greater than φent. In this case, 
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electrosprayed droplets are stabilized against rupture, leading to a desirable spherical 
morphology. For lower flow rates, we may fall in the regime where φov<φRay<φent where 
entanglements are not strong enough to preserve the particle from deforming via stretching 
during the fission process, leading to a deformed morphology. 
These theories were confirmed for BSA-loaded PLGA microparticles when polymer 
concentration (in DCM) was decreased from 10 to 6%, and wrinkled particles were obtained 
instead of dense and spherical particles [43]. Similarly, this trend was observed in paclitaxel-
loaded PLGA microparticles where the morphology changed from spherical to shell-like 
shapes when decreasing polymer concentration from 8 to 6% [27], while a decrease from 2 to 
1% in ampicillin-loaded chitosan gave abnormal shapes instead of spherical particles seen for 
2% [23]. Hollow particles were seen when decreasing the concentration of aqueous elastin-
like polypeptides from 1 to 0.5% while spherical spheres were initially obtained at higher 
concentrations [33]. All these results are a consequence of high solvent concentration, 
hindering complete solvent evaporation by the time the particles reach the collector, which in 
turn resulted in deformed morphology. The effect of polymer concentration was also 
considered with MW where a higher MW (70,200 g/mol versus 17,800 g/mol) provided tailed 
structures or beaded fibers instead of spherical particles for both concentrations [33]. As 
explained previously, this is a consequence of φRay being reached before strong entanglements 
are present within the droplet. This leads to the stretching of the primary droplet (φRay<φent) 
since an increase in MW leads to a decrease in surface tension and thus a decrease of φRay in 
accordance to Equation (5). 
In coaxial electrospraying, flow rates of both core and shell solutions are determinant for 
reproducible morphology and size of capsules, where inner flow rates are required to be lower 
than outer feed rates. Decreasing the inner flow rates led to a thicker capsule shell and 
reduced particle size (Fig. 5E) [56]. When loading paclitaxel and suramin in the PLGA shell 
and poly-L-lactide (PLLA) core of microcapsules, respectively, it was concluded that a Qcore 
ranging between 1.0 and 2.0 mL/h and a constant Qshell of 2.0 mL/h may maintain a stable 
cone-spraying mode and consequently result in uniform and smooth microspheres with varied 
core sizes [30, 63]. 
In electrospraying of emulsions, a decrease in the organic/aqueous phase volume ratio 
(from 20:1 to 6.7:1) led to a degeneration of the spherical shape of particles with a more 
wrinkled surface. This was tentatively explained by a corresponding decrease in viscosity 
which would hinder the shrinkage of droplets during evaporation [45]. 
Similarly, loading of biomolecules into the particles affects the morphology and wrinkled 
particles were observed for a 30% - and above - loading of rifampicin in PLGA particles [24]. 
This is a consequence of the difference in molecule types: PLGA is a linear macromolecule 
whereas rifampicin is a small organic molecule. It was stated that the addition of rifampicin 
decreased the diffusion coefficient of solutes and weakened the intermolecular entanglements 
of PLGA. When the concentration of the drug is higher than a critical value, diffusion is 
slower than solvent evaporation, resulting in the increase of drug concentration near the front 
of the droplets. Drug molecules accumulate and form a layer of semi-solidified skin on the 
surface. With further evaporation of solvent, the intermolecular polymer entanglements in the 
droplet skin predominate, forcing the semi-solidified skin to collapse, leading to wrinkles 
[24]. 
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Fig. 5. Importance of electrospraying parameters. (A-B) Effect of various parameters on 
morphology of PLGA particles: (A) Effect of concentration and molecular weight 
(FR=1mL/h and AV=10kV). (B) Effect of concentration and liquid flow rate (MW=38kDa 
and AV=10kV) [76]. (C) Relationship between mean particle size, electrical conductivity 
and viscosity of PCL solutions (FR=10µl/min, AV=10kV). Square with solid line: mean 
size; circle with dotted line: conductivity. (D) Polydispersivity index of PCL particles 
produced in the cone-jet region as a function of flow rate (AV=10kV). Square line: PCL 
2wt% (viscosity: 2.6 mPa.s); triangle line, PCL 5wt% (viscosity: 4.6 mPa.s); diamond line: 
PCL 10wt% (viscosity: 11.1 mPa.s) [40]. (E) Dependence of the size and shape of 
microcapsules made by coaxial electrospraying on the feed ratio between outer and inner 
solutions [56]. (F) Diagram depicting the influence of parameters on particle diameter (↑: 
increase) [20]. Adapted from [20, 40, 56, 76] with permission. 2009 John Wiley and Sons 
[76]; 2010 Royal Society [40]; 2008 American Chemical Society [56]; 2009 Elsevier 
Science Ltd. [20]. 
 
3.2.2. Size 
 
The size of polymeric particles that contain bioactive molecules significantly influences 
their therapeutic capabilities. For instance, the release rate increases with a larger surface to 
volume ratio of the particles [28] and is dependent on surface diffusion and degradation. 
Control of size is therefore essential for tailoring release properties. The electrospraying 
technique can produce particles with sizes varying from tens of micrometers to tens of 
nanometers [35] and by choosing the right parameters, low polydispersity can be obtained 
with relative standard deviations (RSD) within 2 to 27% of the average size [34, 43]. This is 
advantageous in drug delivery since drug distribution within the matrix can be controlled 
more precisely with a single known particle size, allowing degradation rates and diffusion of 
drugs to be better tailored to fit a desired application [16]. However, this is a constant issue 
when microparticles are made from double emulsion fabrication methods where broad 
distributions are obtained, ranging from 49 to 110% RSD [22, 36].  
When nanoparticles are considered, the control of size and polydispersity becomes even 
more important since they can greatly affect cell response mechanisms where particles are 
internalized by cells. This involves particles lower than 500 nm for uptake by epithelia cells 
for example [18], and lower than 100 nm for applications such as tumor targeting by the 
enhanced permeability and retention (EPR) effect. However, although the electrospraying 
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technique allows the generation of nanoparticles such as pharmaceutical nanoparticles (APIs) 
or non-organic nanoparticles (for coating for instance), when polymeric carriers were used to 
encapsulate drugs, the resulting electrosprayed particles were mainly found to be on the 
micron to submicron size. The minimum size reported so far is 116.1 nm with budesonide-
loaded PCL particles [38] and very few studies are found in the 100 to 500 nm range [28, 33, 
36, 42, 71]. This is likely due to polymer chains used in electrospraying of polymers with 
drugs since a significant molecular weight and polymer concentration are needed in order to 
efficiently encapsulate a drug within the polymeric matrix. The nanosize of electrosprayed 
polymer/drug systems is thus less likely and most systems actually produce micrometric sizes 
as seen in Table 1.  
 
Table 1.  Size and polydispersity (expressed as the relative standard deviation to the average particle 
size (RSD) in %) achieved by electrosprayed polymeric particles loaded with various types 
of therapeutic molecules. 
 
Size domain 
Size range  
studied 
Size with 
lowest 
polydispersity 
RSD 
(%) 
Polymer 
Loaded 
Molecule 
Ref. 
Below 500 nm 
116.1 - 165 nm 165 nm 11.5 PCL Budesonide [38] 
- 247 nm 7.2 
PAA-
cholesterol 
Tamoxifen [42] 
304.9 - 569 nm 304.9 nm 6 TPP-Chitosan Doxorubicin [71] 
255 - 355 nm 335 nm 18.2 PLGA Paclitaxel [28] 
- 370 nm 6.8 
Elastin-like 
polypeptides 
Doxorubicin [33] 
250 - 500 nm 470 nm 2.1 PLA BDP/SS [36] 
500 nm - 1 µm 
510 - 630 nm 630 nm 11.1 PLA BDP/SS [36] 
- 840 nm 21.4 PLA BSA [45] 
580 - 910 nm 910 nm 12 PLGA Rhodamine [22] 
1 - 5 µm 
 
1.12 - 1.34 µm 
1.12 µm 10 PLGA Rhodamine [22] 
1.34 µm 10 PLGA Doxorubicin [22] 
1.64 - 4.77 µm 3.95 µm 12.9 PLA BSA [46] 
- 4.13 µm 26.9 PLA Cisplatin [34] 
2.3 - 4.4 µm 4.4 µm 7.4 PLGA Celecoxib [37] 
Above 5 µm 
 
5 - 5.31  µm 5 µm 15.0 
PLA/PLGA 
(30/70) 
Cisplatin [34] 
5.4 - 5.7  µm 5.4 µm 16.7 PLGA IGF-1 [47] 
6.51 - 12.8 µm 7.5 µm 6.8 PCL Paclitaxel [31] 
7.9 - 10.4 µm 8 and 10 µm 15 PLGA BSA [51] 
5.67 - 9.78 µm 9.39 µm 3 TPP-Chitosan BSA [44] 
- 11.4 µm 7.9 PCL Paclitaxel [27] 
- 11.76 µm 23.7 PLGA Paclitaxel [25] 
- 15 µm 11.3 PLGA Paclitaxel [26] 
14.2 - 15.2 µm 15.1 µm 4.6 PLGA Paclitaxel [27] 
- 20 µm 15.5 PCL BSA [43] 
20.3 - 22.1 µm 21.2 µm 7.1 PLGA BSA [43] 
 
Monodispersity remains a very important factor for micron sizes, especially for release 
properties and Table 1 shows a non-exhaustive summary of the various polydispersities 
(expressed as the relative standard deviation to the average size of one formulation) that have 
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been achieved so far by loaded electrosprayed polymer particles, per size domain. It can be 
seen that several similar sizes can provide very different polydispersivities according to the 
processing parameters and also depend case by case on the polymer/drug/solvent selection. It 
is thus possible to obtain very low polydispersivity with electrospraying (as low as 2.1% [36, 
43]), by tailoring electrospraying parameters, but this is a complex undertaking. 
Monodispersity is obtained with reduced flow rates, increased polymer concentrations 
(higher viscosities), reduced conductivity of the electrosprayed solutions and reduced applied 
voltages [40, 87]. This applies for the stable-cone jet mode known to be the only one able to 
produce monodisperse particles and when parameters such as flow rate are used in the central 
cone-jet region. Indeed, when flow rate is used close to the upper and lower limit of the cone-
jet region, the polydispersivity index of particles increases, as seen in Fig. 5D [40].  
The size of electrosprayed polymer particles is greatly influenced by flow rate and 
polymer concentration, where increased particle sizes are most significantly obtained with an 
increase in flow rate and polymer concentration and a decrease in conductivity (Fig. 5C) [59]. 
However, at increasing flow rates, the size distribution also becomes broader [35] and 
formation of secondary and satellite droplets can take place if the polymer network is not 
entangled enough (φov<φRay<φent). This leads to a bimodal size distribution which is quite 
common in electrospraying and sometimes unavoidable [12, 24, 31, 59]. Some strategies 
have been suggested to separate the two size populations by using a steel plate with a 3 cm 
circular hole as the grounded electrode, which serves to collect only the primary droplet 
population. Often a spatial separation occurs after the droplet break-up where two regions of 
electrospray can be seen during the stable cone-jet mode, since satellite/secondary droplets 
have a larger surface charge density but less mass than primary droplets. Therefore primary 
droplets can be found in the inner core of the spraying cone, while satellite/secondary 
droplets get ejected at the periphery of the cone [24]. By using a plate with a circular hole as 
a screen on top of the collector, satellite/secondary droplets thus are left behind and only 
primary droplets are recovered ensuring monodispersity, although reduced yield may be of 
concern. Hartman et al. measured very small currents (31-57 nA) during electrospraying and 
found that another way to reduce the frequency of satellite droplets is to lower the current by 
lowering the applied voltage or flow rate [14]. However satellite/secondary droplets remain 
difficult to eliminate completely [24].  
These findings are explained by the relationship between size and electrospraying 
variables depicted by Hartman et al. in the stable single cone-jet mode and shown in 
Equations (6) and (7) [14]. The droplet diameter, d, can be modeled using various equations 
generated by De La Mora and Loscertales [88] in 1994, Gañan-Calvo et al. in 1997 [81] and 
Hartmann in 2000 [14] (Equations (6) and (7)) for the single cone-jet mode. They are 
functions of the liquid flow rate, Q, the solution density, ρ, the current, I, the surface tension 
in ambient air, γ, and the liquid conductivity, K (α is a constant). 
 
 
Particle size is directly proportional to droplet size, where an increase in size is obtained 
with increasing flow rate and decreasing surface tension, and is shown to correspond to an 
increase in polymer content [86]. However as stated earlier, an increase in flow rate is also 
responsible for broader size distributions [35], thus a compromise needs to be made between 
particle size and dispersity. This is explained in section 3.1.2.1, where higher flow rates lead 
to smaller φRay, eventually falling in the case where φov<φRay<φent where polymer 
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entanglements are not strong enough to preserve the droplet integrity during electrospraying. 
This unwanted regime will lead to the ejection of offspring, secondary and satellite droplets 
from the primary droplets and broaden the resultant size distribution considerably. The first 
pre-requisite of monodispersity of electrosprayed particles is thus the use of a flow rate that 
ensures φRay>φent, where primary droplets cannot be disrupted by Coulomb fission. As stated 
by Almeria et al., if increasing particle size is highly desired, while maintaining 
monodispersity, increased flow rates could be coupled with higher polymer concentrations so 
that the φRay>φent is still validated [21]. 
When involving the polymer concentration parameter, particle size has been shown to 
increase compared to the theoretical calculations for PLGA microparticles containing 
paclitaxel made from low polymer concentrations (4, 6 and 8% in acetonitrile), while it was 
in good agreement for 10%. This was attributed to the non-spherical shape and high porosity 
of particles made from lower concentrations [28]. The increase in particle size as a function 
of the square root of flow rate was also shown to be sharper for higher polymer 
concentrations. An increase in concentration from 5% to 10% PCL in DCM, however, led 
only to a slight increase in size, for paclitaxel-loaded particles from around 9 to 13 µm [31], 
suggesting that rate is more determinant than polymer concentration for directing the size of 
loaded particles. Indeed, increasing the flow rate from 4 to 8 mL/h when electrospraying 
chitosan solutions significantly increased the size of microparticles at each chitosan 
concentration [44]. However the size did not increase significantly with an increase in 
concentration from 1 to 2%. In a similar study, an increase in polymer concentration from 4 
to 8% (PLGA 50:50 in acetonitrile) resulted in a limited change in the particle size while for 
10%, the sizes were considerably larger. This was explained by the low diffusion rate of 
PLGA chains where a shell of solid PLGA would form on the surface of the droplets. For 
lower polymer concentrations in the 4-8% range, the shell would be thinner but a similar 
overall size would be obtained, while for concentrations higher than 8% a high polymer 
concentration was established on the surface of the droplet with less solvent evaporation, 
resulting in a larger final particle size [28]. All these results underline the strong effect and 
inter-dependence of flow rate coupled with concentration on particle size. 
Drug loading was also shown to affect microparticle size; loading from 0% to 15.8% of 
the anti-cancer drug paclitaxel increased PLGA particle size from around 13 to 15 µm 
although the number of particles analyzed (n) or the technique for size measurement was not 
described in the study [27]. The link between loading and size is however less evident than 
previous variables. In the case of electrospraying of emulsions, the size was shown to first 
decrease and then increase as the BSA:PLA weight ratio decreased from 1:2 to 1:6. This was 
tentatively explained by a decrease in viscosity from less solid mass in the emulsion causing 
the initial decrease in size, and the lower conductivity causing the subsequent increase [45]. 
As explained in section 3.1.2.2, the electrical conductivity is indeed a potent parameter for 
controlling particle size where the scaling laws from Gañan-Calvo show that a decrease in 
particle size can be obtained with an increase in conductivity, according to Equation (8) [81]: 
 
 
The use of a solvent with a higher conductivity can thus decrease particle size as seen when 
comparing PLGA particles made using acetonitrile and dichloromethane as the solvents [84] 
or when adding acetone to a PLA solution of 1,2-dichloroethane (1:1) [46] where 
conductivity was increased from 0.058 to 0.412 µS.cm
-1
 and particles decreased in size from 
4.8 to 1.6 µm. However, it was shown that the use of co-solvent with increased conductivity 
broadened the size distribution with a bimodal character and reduced the spherical 
morphology of PLGA particles [76] and PLA particles [46], respectively. The use of organic 
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salts is more effective to increase conductivity without causing a concomitant deterioration in 
the initial morphology of particles as seen with 2 mM of didodecyltrimethylammonium 
bromide (DTAB) added to an acetonitrile solution of PLGA and paclitaxel [28]. In this case, 
particle size was decreased from 1.2 µm to 355 nm. Other possible electrolytes include 
ammonium hydroxide (0.02 to 0.2% (v/v)) [36]. Although conductivity is pivotal in size 
tailoring, it must be kept in mind that an increase in conductivity reduces the region of the 
stable cone-jet mode and hence standard deviation tends to increase, broadening the size 
distribution [35]. Again this is due to a consequent decrease in φRay which may eventually be 
smaller than φent where the ejection of offspring, secondary and satellite droplets from the 
primary droplets is possible. Such broadening was also observed with increasing surfactant 
concentration, thus conductivity of the solution, as seen for 2-16% Pluronic F127 in PLGA 
solution in acetonitrile, although it did not appreciably reduce the average particle size [28]. 
However, for budesonide-loaded PCL particles, a decrease of Tween 20 from 0.005 to 
0.001% led to a decrease from 884 to 116.1 nm under optimal electrospraying conditions 
[38].  
Emulsions comprising organic/aqueous and protein/polymer phases also have significant 
impact on particle size [45]. Particle size increased with organic/aqueous volume phase ratio. 
This was due to a corresponding increase in viscosity and decrease in electrical conductivity 
which makes it more difficult for the solution to be broken up into smaller droplets in the 
course of electrospraying, thus increasing particle size. Such correlation between size, 
viscosity and electrical conductivity was also seen for β-oestradiol-loaded PCL particles 
where an increase of PCL concentration from 2 to 10 wt% led to a change in viscosity and 
electrical conductivity of the PCL solutions from 2.6 to 11 mPa.s and from 3.4 to 0.8 µS/m, 
respectively. This resulted in a mean particle size increase from 0.3 to 4.5 µm [40]. 
 
4. Electrospraying and drug release characteristics  
 
4.1. Choice of molecules 
 
 Most pharmaceutical drugs and proteins are expensive. For this reason the majority of 
drug delivery studies are first undertaken with model drugs or model proteins, to enable 
optimization of parameters and characteristics of particles in the first instance, before loading 
fragile and expensive drugs/proteins. A non-exhaustive summary of various drugs and 
proteins that have been loaded so far in electrosprayed particles is presented in Fig. 6.  
 As far as proteins are concerned, bovine serum albumin (BSA) has been widely used for 
this „model‟ purpose in traditional encapsulation techniques [89], and to some extent in 
electrospraying [43-46, 51, 53, 68, 90]. BSA is readily available and it offers high stability 
and low cost, which is advantageous in the early stages of optimization. The molecular mass 
of BSA is 66.4 kg/mol, which is similar in size to some growth factors (GFs) used for tissue 
regeneration, providing a more suitable choice than smaller model molecules. Serum 
albumins are also extensively used as an excipient, i.e. as an inactive substance used as 
carrier for the molecules of interest, since they have the ability to bind a wide variety of 
biological molecules, e.g. cationic, anionic, hydrophilic, hydrophobic substances. Many 
drugs, such as anti-coagulants and anesthetics, are also transported in blood while bound to 
albumin [80]. Serum albumins have no adverse effect in most biochemical reactions and they 
have been shown to assist decreasing the initial burst release occurring in most particulate 
systems [91], and stabilize and protect the bioactivity of molecules during the harsh 
conditions of encapsulation [92].  
 Due to its combined advantages, BSA has often been selected as a model protein to be 
encapsulated in electrosprayed particles, in studies focusing on release of proteins or drugs. 
Unfortunately, only a handful of studies can be found where electrosprayed particles have 
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been loaded with the actual protein of interest other than BSA, in part due to their high cost. 
It would be valuable for more studies to progress towards using therapeutic proteins in place 
of these model systems. Some examples of studies who do encapsulate therapeutic molecules 
include growth factors such as insulin-like growth factor-1 (IGF-1) [47], vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF) [48]. Growth factors (GFs) 
are essential actors during natural tissue formation. These polypeptides are produced in-situ 
by cells and transmit signals to modulate cellular activities [9, 93]. During tissue growth a 
complex and orchestrated delivery of several types of GFs occurs and tissue growth is 
dependent on this delivery. Thanks to the current technologies, GFs can now be 
recombinantly produced, albeit at very high cost, and have thus attracted a lot of interest 
among tissue engineers. Many DDPS have attempted to encapsulate and release GFs in a 
sustained manner, mimicking the normal in vivo production. For GFs that were encapsulated 
in electrosprayed particles, we find IGF-1, PDGF and VEGF, which are mostly involved in 
angiogenesis. It must be noted that their molecular mass ranges from around 7 (IGF-1) to 45 
kg/mol (VEGF) and are therefore lower than BSA (66.4 kg/mol). Compared to small drugs, 
proteins are also prone to denaturation, which is often an issue in DDPS production where 
organic solvents are used. The technique of electrospraying however, offers a reduced contact 
of proteins with solvents and most importantly does not require the emulsion step present in 
the traditional fabrication processes. The aqueous/organic interface is thus avoided along with 
its respective shear stresses, mainly responsible for protein denaturation [10]. Electrospraying 
may thus prove to be superior to traditional techniques for loading of proteins, sensitive to 
denaturation. This is further discussed in section 4.5 and 4.6. 
 As far as small molecules are concerned, various drugs have been loaded in electrosprayed 
particles, finding applications in the fields of inhalation therapies, antibiotic delivery, cancer 
treatments and hormonal treatments. In inhalation therapies, the control and monodispersity 
of particle sizes obtained with electrospraying allow for more efficient administration of 
drugs by a reduction of the required dose and higher drug availability for treatment. The 
major drugs that have been utilized to date by direct electrospraying of the drug solutions or 
by encapsulation in PLA particles, are beclomethasone dipropionate (BDP) [35-36] and 
salbutamol-sulfate (SS) [36], which is delivered through a bronchodilatator and is 
commercially known as ventolin. These small molecules (both less than 1 kg/mol) are used in 
the treatment of asthma and other chronic obstructive lung diseases and need to be inhaled for 
direct effect on bronchial smooth muscle [35]. BDP and SS have very different properties; for 
one they are hydrophobic and hydrophilic, respectively. For this reason electrospraying 
represents a superior alternative to traditional techniques since it does not require for the 
experimental parameters or setup to be changed, being renowned as a method suited to 
molecules that do not process well (such as those with different solubilities) [36]. 
Methylparahydroxybenzoate (MPHB) is a model drug that can be used for mimicking BDP 
and it has been demonstrated that the electrospraying of both drug solutions were similar, 
validating its use as a model molecule [35].   
 Antibiotics have also been encapsulated in electrosprayed particles, such as rifampicin, an 
anti-tuberculosis drug, [24] and ampicillin [23] which function to treat bacterial infections 
(Fig. 6). Similarly to inhalation drugs, ampicillin and rifampicin have a small molecular mass 
of 350 g/mol and 823 g/mol, respectively, an important contrast with the mass of polymer 
chains used in electrospraying, ranging up to hundreds of kg/mol. 
 Anti-cancer drugs remain the most frequently tested drugs in electrospraying. 
Encaspulated anti-cancer drugs include cisplatin [34], paclitaxel (sold commercially as 
Taxol
®
) [25-32, 63], a hydrophobic molecule, suramin [30, 63], and doxorubicin [22, 33, 71], 
both hydrophilic and shown in Fig. 6. In cancer therapies, multiple and temporal drug 
delivery is generally required for treatment. However, previous methods to obtain double-
walled microspheres such as the oil-in-oil-in-water (o/o/w) emulsion require several hours of 
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rapid stirring to create an emulsion, which is detrimental to the drug, limiting loading, with 
possible degradation issues and difficulties in controlling the drug distribution [30]. Coaxial 
electrospraying is thus advantageous in this instance since it allows: encapsulation of 
different types of drugs in different compartments in one single step; encapsulation of both 
hydrophobic and hydrophilic drugs; and tailoring of release (sequential or coupled) with the 
tailoring of electrospraying parameters and physical disposition of drugs within the core and 
shell [30, 63].  
 Less commonly in the field of hormonal treatments, sex hormones or drugs have also been 
encapsulated in electrosprayed particles. β-oestradiol, a contraceptive and 
hypocholesteraemic drug of low molecular weight (272 g/mol) was for instance encapsulated 
in PCL particles [40], while tamoxifen (371.5 g/mol), a drug that blocks the effects of 
oestrogen in breast tissue was encapsulated in lipid-based particles [41-42]. 
 Miscellaneous drugs that have been encapsulated in electrosprayed particles include α-
lipoic acid, an agent shown to be effective in treating various diseases (diabetes, 
atherogenesis) [57]. Anti-inflammatory drugs, such as celecoxib, budesonide and naproxen 
have also been encapsulated in chitosan, PCL, and PVP particles, respectively [37-39].  
Celecoxib is widely used in the treatment of osteoarthritis but has undesirable properties such 
as high cohesiveness and low solubility. The use of electrospraying for encapsulating 
celecoxib in PLGA microparticles allowed an increase in celecoxib dissolution rate, which is 
desired to improve oral bioavailability [37]. 
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Fig. 6. Structures of some drugs and proteins which have been encapsulated in electrosprayed 
particles [94]. 
 
4.2. Loading and encapsulation  
 
4.2.1. Definitions and methods 
 
Electrospraying is an encapsulation process in which efficiency is measured by the 
traditional encapsulation efficiency (EE) and loading capacity (LC) parameters commonly 
used in the field. Encapsulation efficiency represents the weight of biomolecules effectively 
loaded in particles (wLoaded) with respect to the initial weight of biomolecules available (wTotal) 
(Equation (9)). Loading capacity is the weight of biomolecules effectively loaded in particles 
(wLoaded) as a fraction of the total weight of particles (wParticles) (Equation (10)): 
 
Extraction is the most commonly used process to determine these parameters. Briefly, 
particles are dissolved in an organic solvent, usually identical to that used to initially 
solubilize the polymer, followed by the addition of an aqueous solution. The mixture is 
vortexed to extract the encapsulated biomolecule to the aqueous phase, eventually followed 
by centrifugation to separate the oil and water phases. The aqueous phase is then collected 
and analyzed. In some cases, organic solvent is left to evaporate before addition of the 
aqueous phase [27, 29, 31]. Since most studies encapsulate BSA, the standard assay for 
concentration determination is the micro-bicinchoninic acid (µ-BCA) protein assay [31, 43, 
51], and sometimes the Bradford assay [52]. When small molecules containing chromophores 
or large quantities of protein are loaded, high-performance liquid chromatography (HPLC) 
[25, 27, 30-31, 63] and UV spectrophotometer [36] have been used. In all cases, calibration 
curves (produced by serial dilutions of the biomolecule in question) allow the quantification 
of encapsulated contents. 
From the literature, it appears that most studies only undertake one extraction, with the 
exception of Nie et al.‟s study where a total of three extraction cycles were performed for 
suramin recovery [30]. Doing only one extraction is quite restrictive considering that 
E(%)=100D/(1+D), where E is the amount extracted and D is the distribution coefficient. 
BSA is likely to have a relatively high distribution coefficient into aqueous solutions and may 
give high extraction values with only one cycle, however for biomolecules that have a lower 
distribution coefficient, two or three extraction cycles are necessary to maximize recovery. In 
general terms, two or three smaller extractions are always more efficient than one large one 
[95].  
The choice of solvent for extraction is paramount to success. DCM is widely used for 
general extractions and extractions of loaded electrosprayed particles. DCM is an excellent 
choice for extraction: it is immiscible with water and is more dense and volatile, allowing an 
easy removal by evaporation if required. Its drawback is that being a chlorinated solvent, like 
chloroform, DCM has a greater tendency to form emulsions than non-chlorinated solvents 
[95]. This might be an issue for full recovery of biomolecules. 
A final important consideration with the extraction process is that it does not represent the 
amount of biomolecules effectively encapsulated/loaded in particles but comprises also non-
encapsulated molecules which may be simply adsorbed on the surface, (which are responsible 
for the initial burst release often seen with such systems). This is an issue since very high EE 
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are reported in the literature but there is rarely sufficient description of quantification of 
adsorbed/encapsulated molecules. Some quantification was attempted in a study from Ding et 
al., where the particles received an ultrasonic treatment after dispersion in water, followed by 
freeze-drying. The EE of particles from this batch was reduced over 18%, corresponding to 
the loss of adsorbed molecules on the surface of particles, readily dissolved in water during 
the treatment [31]. Some EE/LC numbers are therefore to be considered with caution if 
measured by the extraction method, as they are not representative of the real amount of 
encapsulated/loaded molecules; this is a real shortfall in most studies. 
Interestingly, the determination of EE and LC is also presented via a “non-entrapped” 
method proposed by Xu et al. [44-45]. Particles were centrifuged at 20,000 g at 15°C for 30 
min and the amount of free molecule (BSA in this case) was determined in clear supernatant 
by UV spectrophotometry at 280 nm using the supernatant of non-loaded particles as a basic 
correction. LC and EE were calculated according to Equations (11) and (12): 
 
 
where A is the total amount of BSA, B is the free amount of BSA and C is the particles 
weight. A variant of this technique was used by Arya et al. (10,000 g at 12°C for 10 min) 
[23] and Enayati et al. (β-oestradiol, 4300 rpm at room T for 45 min) [40]. This method does 
not necessarily take into account losses during particle preparation. 
 
4.2.2. Influence of parameters on loading and encapsulation 
 
In traditional encapsulation processes, EE and LC are typically affected by the processing 
parameters, including particle formation temperature. For example EE in double emulsion 
procedures is dependent on the balance between solvent evaporation rate and immiscibility 
between water and particle, rate of polymer precipitation and thus hardening rate of the 
sphere wall [2]. In electrospraying, similar variables such as the nature of the polymer, 
protein/polymer weight ratio, along with flow rates for instance, are parameters influencing 
EE and LC, and will be presented hereafter.  
 
4.2.2.1. Loading capacities 
High loading capacities are always desirable for an increased availability of the 
therapeutic molecule in targeted areas with minimal use of carrier materials. Nevertheless, 
this can induce possible changes of particle morphology that occur with increased loading, 
and thus possible alteration of release profiles. In a study from Hong et al., it was proven that 
an increase in the loading capacity led to a loss of sphericity of microparticles [24] which in 
turn affected the release profiles. The scaling laws of electrospraying were nevertheless 
verified with almost no theoretical variation from non-loaded to loaded particles. The authors 
stipulated that the shrinkage and drying processes were responsible for such variation of 
morphology. Actual loading capacities in electrospraying have also been shown to be slightly 
decreased compared to theoretical loadings. For instance a loss of 20% was seen when 
loading paclitaxel in PCL and PLGA microspheres [27]. Loadings also affect burst release 
with a higher loading leading to a higher burst release. This was observed for PLGA 
microparticles when a loading from 10 to 20% of paclitaxel almost doubled the burst release 
for 15 µm-particles [26], and a loading from 10 to 50% of celecoxib increased the burst 
release from 39 to 54% [37] for 2-4 µm-particles. 
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In terms of parameters affecting the loading capacity, an increase in protein/polymer 
weight ratio dramatically decreased the loading capacity in the case of emulsions of BSA in 
PLA solution [45], while it increased for solid dispersion of BSA in chitosan solution [44]. In 
the case of coaxial electrospraying, drug loading could be increased by increasing inner 
protein aqueous solution flow rate or increasing inner protein concentration [51]. 
 
4.2.2.2. Encapsulation efficiencies 
Electrospraying is known as a technique which can give high encapsulation efficiencies 
(EE), and indeed has been shown to reach 100% EE for doxorubicin and rhodamine-loaded 
PLGA particles [22]. Electrospraying also presents the great benefit that encapsulation of 
both types of drugs, hydrophilic and hydrophobic, are efficiently obtained compared to 
traditional methods [22, 36], mainly since there is no need of an emulsion step. In emulsion-
based methods, the presence of both aqueous and organic phases may indeed lead to 
preferential diffusion of the drug to one phase or the other according to their 
hydrophilicity/hydrophobicity characteristics and thus reducing final EE. This is avoided with 
electrospraying where emulsions are not required. 
EE depends case by case on the combination of drug/solvent/polymer selection, where the 
hydrophilic nature of these components plays an important role. This may be illustrated by 
considering the nature of the polymer itself, for example the encapsulation of BSA in a more 
hydrophobic polymer such as PCL has led to 28% EE compared to 40% for PLGA 
microparticles electrosprayed in the same conditions [43]. The use of hydrophilic additives 
should also be considered and it has been shown that Pluronic F-127, a highly hydrophilic 
copolymer used as a surfactant, increased encapsulations efficiencies from 53.4% to 76.7% 
by using 5% and 10% of Pluronic respectively in PLGA microparticles loaded with BSA, by 
enhancing the w/o emulsion stability. It was further stated that the use of a probe sonication 
to form the emulsion could enhance the EE [43].  
An increase in loading generally leads to a decrease in EE, as seen in electrosprayed 
PLGA films loaded with paclitaxel, where a 5, 10, 15 and 30% loading respectively led to 80, 
71.9, 66.4 and 63% encapsulation efficiency [29]. This was attributed to the partition 
coefficient, referring to the equilibrium solubility of the drug in the polymer against the 
equilibrium solubility of the drug in the solvent and responsible for diffusion of the drug into 
the polymer phase. With paclitaxel being more hydrophobic and soluble in organic solvents, 
increasing the loading could have led to preferential diffusion into the solvent, and thus 
reduced the encapsulation efficiency [29]. In a study from Xie et al., for similar polymer 
solutions and spraying conditions, an increase of paclitaxel loading from 8% to 16% slightly 
decreased EE from 82% to 78% [27] in PLGA microparticles. This was also shown for PLA 
microparticles encapsulating BSA where EE decreased with increasing BSA/PLA ratio and 
increased with organic/aqueous phase ratio. This latter may be explained by an increase in 
viscosity when increasing the organic/aqueous phase ratio, leading to better encapsulation 
[45]. Furthermore, a strong correlation was found between BSA/PLA weight ratio and 
organic/aqueous phase ratio with respect to encapsulation efficiencies. Size affects 
encapsulation efficiencies as well, where smaller particle sizes lower the EE [36]. 
In the case of coaxial electrospraying, higher EE in both core and shell can be obtained by 
encapsulating hydrophobic drugs in the core and hydrophilic drugs in the shell [30]. In 
monoaxial electrospraying, similar EE were found for hydrophobic and hydrophilic drugs 
(54% BDP and 56% SS, respectively) in PLA nanoparticles, demonstrating the versatility of 
the technique. Loss of drugs can, however, be an issue in electrospraying, mainly caused by 
spreading of the particles to the receiving vessel walls and other manufacturing equipment. 
This was measured as 20% for SS-loaded PLA nanoparticles sprayed in ethanol. When 
electrospraying in a cross-linking solution however, an increase in the concentration of the 
cross-linking agent (10% against 5%) led to a significant increase in encapsulation efficiency 
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of BSA [44]. This was due to an increased intermolecular interaction of the polymer and 
cross-linking agent when increasing their respective concentrations, inhibiting the loss of 
BSA into the collection solution and improving EE. When gelation was incomplete, as seen 
for higher flow rates, more BSA was lost in the collection solution [44].  
 
4.3. Molecule dispersion 
 
Controlled dispersion of the drug within the polymer matrix is of upmost importance for 
consistent release. It was previously stated that drug concentration in a particle matrix tends 
to decline as we move outwards from the centre with the increase of the particle diameter as 
seen in rifampicin-loaded particles [24]. This is explained by the diffusion mechanism of 
solutes, stating that an increase in the droplet size provides a longer distance and time for 
diffusion of solutes, leading to a drug gradient within the particle. 
An electrosprayed droplet of polymer contains macromolecules which move and diffuse 
during solvent evaporation, providing the final polymer network. The level of intermolecular 
entanglement among macromolecules dictates these parameters, affecting the diffusion rate 
of macromolecules towards the center. When adding small molecules like drugs to this 
system, they generally diffuse easily towards the droplet center due to the absence of 
intermolecular action. However the intermolecular entanglement of polymer macromolecules 
is weakened, leading to a decrease in the diffusion coefficient of solutes expressed by the 
Stokes-Einstein Equation (13): 
 
where kB is the Boltzman‟s constant, η the viscosity of solvent, T the temperature, and RH the 
hydrodynamic radius of solutes [24]. Therefore by increasing the concentration of small 
solutes in a polymer droplet composed of big macromolecules, the diffusion coefficient 
decreases. Above a critical concentration value, the diffusion of solutes becomes slower than 
solvent evaporation and the small molecules are trapped on the surface of the droplet, leading 
to a molecule saturated layer of semi-solidified skin [24, 32]. Such a configuration is not 
ideal for the physical and release properties of particles, since with further evaporation of the 
droplet, the skin moves towards the droplet center, leading to particle collapse and a final 
wrinkled morphology, which does not lend itself to sustained and reproducible release 
properties. This critical concentration value was found to be 30% w/v in the case of 
rifampicin in a PLGA/chloroform system and led to the loss of particle sphericity and 
subsequent increased burst release compared to the sustained release from spherical particles 
obtained with 10% w/v loading of rifampicin [24]. 
Ideal and homogeneous molecule dispersion, which is preferable for sustained release, is 
therefore obtained for low loadings, smaller particle size (which limits the drug gradient 
effect) and a good balance between the diffusion and evaporation mechanisms. If high 
loadings are needed, it is important to control diffusion and ensure that it does not become 
lower than evaporation. This can be balanced by using a slow evaporating solvent (such as 
DMF). 
A few techniques have been used to assess the integration of drugs within the polymer 
matrix of electrosprayed particles, although they do not allow for physical visualization of 
drugs within the droplets (although confocal laser scanning microscopy may be used to look 
at fluorescently-labeled drugs). Differential scanning calorimetry (DSC) relies on the fact that 
if a drug is well dispersed in the polymer matrix, the melting transition of the drug will be 
suppressed either partially or completely [31]. This theory was used for Taxol
®
-loaded PCL 
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particles where only a slight heat flow peak of Taxol
®
 was observed in the physical mixture 
of PCL and Taxol
®
  [31]. The authors concluded that the drug was well-dispersed within the 
matrix. The same theory was used for paclitaxel-loaded PLGA and PCL microparticles where 
no peak at all was seen in the 150-250°C temperature range, while paclitaxel normally has an 
endothermic peak of melting at 223°C [27]. From this result, the authors stated that the 
paclitaxel was in an amorphous or disordered-crystalline phase of a molecular dispersion or a 
solid solution state in the polymer matrix. The same conclusion was made for hydrogel beads 
encapsulating paclitaxel-loaded PLGA microspheres [25]. This was further seen in 
electrosprayed PLGA films loaded with the same drug [29]. The authors even annealed their 
samples for 3 days at 60°C to facilitate a higher diffusion rate for dispersed drug molecules, 
but still no crystalline peak of paclitaxel was observed for annealed samples, leading to the 
conclusion that the drug was in a solid solution state within the matrix, as compared to a 
metastable molecular dispersion [29]. A similar theory was used for BDP and SS-loaded PLA 
nanoparticles where no melting peak at all was seen for BDP-loaded particles and only a 
smaller and broader peak was seen in SS-loaded particles [36]. The crystallinity of PLA was 
changed in the presence of both drugs, namely higher when SS was encapsulated and lower 
when BDP was encapsulated. This was tentatively explained by the presence of water, since 
SS was emulsified before electrospraying, thus reducing evaporation rate, allowing for more 
polymer diffusion and chains re-arrangement, and was thus responsible for the higher value 
for crystallinity [36]. The crystallinity of all materials (BDP, SS and PLA) in the nanoparticle 
formulations were decreased although the crystalline intensities were distributed as 80% for 
BDP and 20% for PLA, or 54% for SS and 46% for PLA. Importantly, no new peaks were 
seen in the DSC profiles, indicating no strong physical or chemical interactions were present 
between the drugs and polymer. A similar result was observed for celecoxib-loaded PLGA 
microparticles, where the melting endotherms of celecoxib shifted down or disappeared 
according to decreased drug content, suggesting that the drug was molecularly dispersed 
within the PLGA matrix [37]. The disappearance of the Tamoxifen peak for loaded PAA-
Cholesterol nanoparticles suggested the same result [42].  
X-ray diffractometry (XRD) may also be used for determining the physical state of a drug 
within polymeric matrices since characteristics of the peaks mark the degree of crystallization 
of the drug with the matrix. XRD previously showed that paclitaxel was in an amorphous 
form in the PLGA matrix, even for up to 30% drug loading, since no peak was seen in the 
expected range of temperature (200-250°C) when analyzing the polymeric matrix [29].  
Analysis of surface chemistry by X-ray photoelectron spectroscopy (XPS) can also give 
information regarding the distribution of drugs within microparticles, by examining the C, N 
and O element compositions. This technique has been used to show that paclitaxel was 
present on the surface layer of PLGA microparticles (with up to 0.8% atomic mass 
concentration), a phenomena which is argued to be responsible for the initial burst release 
seen in the in vitro release study [27]. XPS showed that the amount of nitrogen increased 
with increasing paclitaxel contents (0-30% loading) in electrosprayed PLGA films, attesting 
of the presence of the drug. 
Confocal laser scanning microscopy (CLSM) is another way of qualitatively looking at 
fluorescently labeled biomolecules encapsulated within particles. This method allows for 
screening of cross-sections of a loaded particle through the entire particle, for further 3D 
reconstruction. This powerful tool proves to be very useful for visualizing in 3D the 
biomolecule distribution inside the particles after production, and studying the mechanisms of 
release from particles. CLSM has been used successfully for other fabrication methods such 
as spray-drying [96], however it has yet to be extensively utilized for visualization purposes 
with electrosprayed particles [22], although it would be very valuable, especially in 
combination with the aforementioned analysis techniques for a more thorough 
characterization of molecule dispersion. 
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4.4. Release kinetics  
 
Polymeric microparticles for controlled drug delivery have been extensively studied in the 
last 50 years and various reviews detail their preparation, the factors affecting the release and 
the current difficulties faced during processes [1-2, 4, 10, 97]. Most of these reviews 
encompass microparticles made from traditional fabrication techniques and limited 
information is available on release kinetics from electrosprayed particles.  
In general terms, release occurs through two different mechanisms: passive diffusion and 
polymer degradation. Ideally a controlled release system would show a zero-order release 
profile, meaning a constant release rate over time. However the release profile from particles 
is usually split in two distinct processes:  
1. The initial burst release of molecules contained on and in the surface of the particle due 
to the leaching occurring at the outer wall of the particle as it becomes hydrated [2]. 
2. The slower and more constant release of molecule from the inner part of the particle. 
Release profiles can be affected by physical and chemical factors: the nature of the 
polymer (molecular weight, blending, crystallinity), the nature of the loaded molecule, its 
distribution and activity, the morphology of microspheres, their porosity and size distribution 
[1-2]. In electrospraying, similar parameters are able to tailor release kinetics and they are 
discussed in the next section. Table 2 illustrates various electrospraying studies with the 
release profiles and corresponding morphologies.  
 
Table 2.  Drug loading and release characteristics of electrosprayed particles loaded with various 
bioactive molecules. Adapted from [22-24, 27, 31, 37, 40, 43, 45, 51] with permission. 
2006, 2008, 2005, 2011 Elsevier Science Ltd. [22, 24, 27, 31, 37, 45, 51]; 2007, 2009 John 
Wiley and Sons [23, 43]; 2010 Royal Society [40]. 
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Size  
The size of particles which encapsulate bioactive molecules is paramount in tailoring 
release profiles. A larger surface area to volume ratio (smaller particles) leads to faster 
release since particles are more easily penetrated by fluids, favoring easier diffusion of drugs 
and faster degradation of the polymer matrix. However, it is important to emphasize that it is 
not size itself that controls the release profiles but it has more to do with the 
polymer/drug/solvent selection and processing parameters that are used in each case, as 
explained in section 3.2.2. Therefore size is a result of other variables which have an inter-
dependent effect and need to be appropriately correlated to truly control release kinetics.  
In a study by Enayati et al. for instance, β-oestradiol-loaded PCL particles had similar 
release pattern for mean sizes of 0.34, 0.8 and 4.6 µm, however release was 45, 42 and 36%, 
Ref. Polymer Molecule LC EE 
Size 
(µm)
Morphology
Cumulative release profiles 
(%) (y axis)
[45] PLA BSA 74-91% 23-81% 0.8-4
[43] PLGA 50:50 BSA - 20-77% 20-22
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respectively, after 45 days, thus showing a reduced release for increasing particle size [40]. 
This increase in size was actually due to an increase in polymer content (2, 5 and 10%, 
respectively), showing that polymer concentration do indeed provide bigger particle sizes but 
may also provide reduced release rates at the same time. In this study, due to the nature of the 
polymer (PCL) where degradation is unlikely to have occurred over a seven-week period, the 
release was due to diffusion of β-oestradiol from the particles, proving that drugs loaded in 
smaller particles comprising less polymeric bulk material are prone to better diffusion outside 
the polymeric matrix and thus enhanced release [40]. However, burst release is also more 
likely to happen from smaller particles. This was observed for paclitaxel-loaded PCL 
particles where two formulations with similar sizes (9.45 and 9.52 µm) showed a similar 
release pattern and amount released, while a slight decrease in size to 8.68 µm gave the same 
release pattern but with a higher burst at the beginning (11% compared to 7% burst within a 
day). This was again attributed to a higher polymer concentration (5% PCL in DCM for the 
smaller size and 7.5% for the larger size) which influenced the  final size, where larger 
particles had a denser polymer matrix and thus a reduced rate of diffusion, in turn reducing 
the initial burst release [31]. When working with smaller concentrations, size is less affected 
although release profiles can still show great differences. For instance for an increase in 
chitosan concentration from 1 to 2%, size was slightly higher, but not significantly (7.48 and 
8.11 µm, respectively), while a higher burst was observed for the reduced concentration (7 
and 2% after 4 days) leading to a final cumulative release of 33% and 21% for the 1% and 
2% concentration formulations, respectively. Although an increase in polymer concentration 
is generally shown to increase size and decrease release rates/burst release at high 
concentrations, the contrary is seen for loadings. An increase in loading is generally 
responsible for increased sizes too, but generates faster release rates and burst, especially on 
the submicron scale [44]. This can be seen for doxorubicin-loaded chitosan nanoparticles for 
example, where an increase in loading from 0.25 to 1% doxorubicin increased the resultant 
particle size from 527.3 to 873 nm and led to 40% burst release within 3 hours while only a 
20% burst release was observed for the smaller sizes [71]. For microparticles, however, size 
is less affected by loading although release is affected. For instance, in paclitaxel-loaded PCL 
particles, when loading was increased from 7.9 to 15.8%, the resultant size was very similar 
(15.2 and 15.2 µm, respectively) although burst release was 10 and 20% after 1 day, and the 
final cumulative release reached 57 and 62%, respectively [27].  
In the case of emulsions, the organic/aqueous phase factor has little effect on release 
profiles although size is significantly affected, as a consequence from decreased conductivity 
with increased organic phase, and thus increased size, as explained in section 3.2.2. This was 
seen for BSA-loaded PLA particles where at a constant ratio of 1:4 BSA/PLA, but increased 
organic/aqueous phase ratio ranging from 6.7:1 to 20:1, size increased from 0.8 to 1.9 µm but 
showed similar release pattern and amount released [45].  
Another significant factor affecting release kinetics is the degree of agglomeration of the 
particles. The burst release process is mainly diffusion-driven while the second process 
providing a slower release is erosion-driven. It was shown by Almería et al. that the burst 
release stage was greatly affected by particle agglomeration and particle size, whereas the 
slower release part was much less dependent on particle size [22]. Agglomeration however 
was shown to affects release kinetics for hydrophilic biomolecules, since sizes of particle 
clusters result in orders of magnitude larger than individual particles. This aggregation 
compromises the reproducibility of release profiles and provides less cumulative release than 
dispersed particles (Rhodamine B from PLGA electrosprayed particles) [22]. Coating 
techniques may thus be used for preventing aggregation when electrospraying in solution and 
enables tight control over particle size.  
 
Morphology  
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Along with size distribution, morphology is another major contributor for controlling drug 
release behavior and like size, morphology is directed by the polymer/drug/solvent selection 
and processing parameters [31]. It was indeed shown that wrinkled particles led to a burst 
release of 50% of cumulative release of BSA form PLGA particles in the first day, which was 
not seen for spherical particles with the same size distribution (21 µm average diameter, 2 µm 
SD) [43]. This is a direct consequence of lower polymer concentration used in wrinkled 
particles (6%) compared to dense and spherical particles made of 10% PLGA. More pores 
were found in wrinkled particles allowing for molecule adsorption instead of encapsulation. 
Water penetration is more accessible in porous particles and leads to the rapid diffusion of 
adsorbed molecules, responsible for the high burst release. In denser particles, the rate of 
water penetration is reduced, allowing for desirable zero-order release kinetics. 
Similarly to polymer concentration, molecular weight (MW) is another important factor 
for tailoring particles and their release profiles, since both parameters direct the viscosity of 
solutions. This was illustrated with PLGA capsules containing IGF-1, made of low (5-15 
kDa) and high MW (40-75 kDa) [47]. The release profiles were similar, triphasic in nature, 
but with an initial burst which was more prevalent for the low MW formulation, for same 
PLGA concentration and IGF-1 loading. The burst was 5.5% compared to 7% and led to a 
final cumulative release of 10 and 12% for high and low MW formulations, respectively. The 
morphology of high MW particles was spherical while the low MW particles displayed an 
irregular morphology. This was a consequence of weaker chain interactions in the low MW 
PLGA where packing of polymer chains was looser than that of high MW PLGA, which 
allowed the encapsulated IGF-1 to diffuse through the polymer more easily [47]. 
The solvent is another means to control particle morphology, due to different evaporation 
rates that lead to more or less porous structures respectively. This will ultimately condition 
the release kinetics as well, as seen with PLGA particles containing doxorubicin, 
electrosprayed from a 2,2,2-trifluoroethanol (TFE) solution and TFE-dimethyl sulfoxide 
(DMSO) mixture (vapor pressures at room temperature of TFE and DMSO are 0.08 kPa and 
10.09 kPa respectively). As expected, PLGA particles electrosprayed from TFE were more 
porous than the ones from TFE-DMSO, leading to 77% compared to 52% of drug released by 
diffusion (burst), respectively [22].  
 
Nature of polymer 
It is accepted that degradation of polymeric particles initially occurs in amorphous regions, 
followed by a slower degradation of the crystalline regions of particles [2]. Freiberg et al. 
stated that low crystallinity allows better drug dispersion and increased drug-polymer 
interactions while the degree of crystallinity is also influenced by the drug loading and the 
concentration and removal rate of organic solvent [2]. Therefore, the use of polymers with 
highly crystalline structures such as PCL enables the production of microparticles with 
uniform and reproducible physical characteristics [59], but might be inadequate for optimal 
drug dispersion and release characteristics. For instance, in a study from Ding et al., the 
cumulative release of Taxol
® 
from electrosprayed PCL particles (65k) did not exceed 37% of 
the total amount of encapsulated Taxol
®
 after 10 days of release (tested up to 50 days), 
suggesting that a high percentage of drug aggregated after contact with the polymer [31]. In a 
similar fashion, a study by Xie et al. showed that PCL microparticles loaded with 8.1% 
paclitaxel were able to release only 32% of this load after 30 days of in vitro incubation while 
PLGA microparticles loaded with the same amounts and electrosprayed with the same 
conditions reached 60% of cumulative release [27]. Regions of high crystallinity and 
aggregated protein may likely contribute to the incomplete release of the protein [67]. 
Responsive polymers such as elastin-like polypeptides can also release biomolecules, such 
as doxorubicin, according to pH variation. However in all cases (pH: 2.5, 5.5 and 7.5), all 
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systems suffered from burst release were maximum release was achieved after 15 min only, 
and therefore they did not provide sustained release [33].  
 
Nature of drug 
Interactions between loaded molecules and polymers direct the location of molecules 
within the polymer matrix (either encapsulated in the core or adsorbed on the surface of the 
particle) and affect the kinetics of release [36]. In the case of coaxial electrospraying for 
loading of multiple drugs within microcapsules, it was shown that the nature of the drugs and 
their location within the microcapsules affected the release patterns: loading of hydrophilic 
drug in the shell and hydrophobic drug in the core provided a sequential release, while the 
opposite led to the drugs being released in parallel [30].  
The physicochemical affinity of the drug with the polymer system has a great influence on 
release kinetics. For similar size distributions and loadings, dramatic differences can be 
observed when varying the hydrophilicity/hydrophobicity of the drug encapsulated. For 
instance when rhodamine B (RHOB) and rhodamine B octadecyl ester perchlorate (RHOBOEP) 
were used as hydrophilic and hydrophobic drug surrogates respectively, 98% of RHOB was 
released within 1 day, while only 6% of total RHOBOEP was released after 5 days. This was 
explained by the strong affinity of RHOBOEP with PLGA, preventing any initial burst release 
(RHOB and RHOBOEP have octanol/water partition coefficients such that log KOW = 1.48 and 
8-9 respectively). When compared with doxorubicin (DOX) (log KOW = 1.85), an 
intermediate behavior was observed where 60% of the drug was released in the first 24h and 
further 20% was released after 5 days. This was attributed to the different partition 
coefficients of the two substances within PLGA [22]. The release of RHOB will occur rapidly 
by diffusion of molecules inside the polymer matrix while DOX - having a greater partition 
coefficient within PLGA - remains entrapped longer in the hydrophobic porous regions of the 
matrix.  
 
Additives 
The use of additives can greatly affect the release kinetics, such as the use of polyethylene 
glycol (PEG), commonly used in traditional encapsulation processes. Due to its 
hydrophilicity, PEG increases the degradation rate of the main polymer matrix by rendering 
the overall polymer network more hydrophilic, increasing swelling and thus accelerating 
release [98]. 
In co-axial electrospinning, for instance, an aqueous PDGF solution was encapsulated in a 
blend of PCL:PEG nanofibers [99]. PEG acted as a porogen and PDGF release reached 100% 
in 35 days with a relatively linear release profile, while less than 1% of PDGF was released 
from the PCL nanofibers with no PEG in the shell. The rate of protein release was shown to 
be controlled by the molecular weight and concentration of PEG [99]. Johnson et al. showed 
that the amount of PEG co-lyophilized with PLGA before encapsulation in discs was the 
dominating factor in the rate of nerve growth factor (NGF), allowing modulation of the 
release [100]. Nevertheless, for particle fabrication methods based on emulsions, the 
efficiency of PEG was mainly observed when the therapeutic molecules were lyophilized 
with PEG before emulsion. When adding PEG directly in the polymer solution instead, 
encapsulation efficiencies and/or release amounts have been shown to be reduced. For 
instance, the encapsulation efficiency of transforming growth factors beta 1 (TGF-β1) in 
PLGA microspheres was reduced from 83% to 54% for PEG contents of 0 and 5%, 
respectively, and also showed a decreased cumulative mass of released GFs [101]. In another 
study intended to incorporate brain-derived neurotrophic factor (BDNF) in microparticles, a 
blend of PLGA:PEG was compared to a blend of PLGA:PLGA-poly(ε-carbobenzoxy-L-
lysine)(PLL)-PEG. The final cumulative release showed a 7-fold increase for the second 
blend, showing the potential of PEG used in a copolymer compared to a blend [92].  
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These results may serve as a useful guide for the use of PEG in electrosprayed particles 
and tailoring of release kinetics. 
 
Loading/EE/in vitro release and processing parameters 
In electrospraying, the drug/matrix ratio and organic/aqueous phase ratio affect EE, LC 
and in vitro release in different fashions as shown in a study encapsulating BSA in a PLA 
matrix [45] and summarized in Table 3. As mentioned before, EE decreased with increasing 
BSA/PLA ratio and increased with organic/aqueous phase ratio. However opposite results 
were observed for in vitro release where: release was reduced with increasing 
organic/aqueous phase ratio and was enhanced by the increase in the BSA/PLA ratio. In the 
same study it was shown that increasing BSA/PLA ratio dramatically decreased the BSA 
loading [45]. These results show how complex the optimization of parameters can be, 
especially in the case of emulsions. Nevertheless the study summarized in Table 3 represents 
only one case and may not be true for every polymer/drug/solvent selection.  
High drug contents are generally responsible for faster release rates [44]. For higher drug 
loadings, initial rate of drug release increases as seen for 30 and 50% loading of rifampicin in 
PLGA-loaded particles while a 10% loading provided zero-order release profile. It was stated 
that the drug concentration affects the drug distribution in the particle matrix, with a gradual 
increasing gradient of concentration present from the centre of the particle towards the 
surface, which was proportional to the drug concentration [24]. In the case of microcapsules 
of PLGA containing an aqueous solution of BSA obtained by coaxial electrospraying, a 0.5% 
loading indeed led to an increased burst release (almost double) as compared to the 0.3% 
loading, although the release rates were identical once passed the burst release [51]. A similar 
result was observed for paclitaxel-loaded PLGA microparticles where 10 and 20%-loaded 
particles showed similar release kinetics, with only a higher initial burst release over the first 
2 days for the 20% formulation, followed by identical sustained release kinetics from both 
formulations for the remaining 28 days [26]. By increasing the drug content in a similar 
matrix type, a higher amount of porosity is created in the matrix, thus the drug diffuses more 
easily through though the matrix, generating an increased burst release [37]. 
 
Table 3. Influence of organic/aqueous phase ratio and protein/polymer phase ratio on various 
parameters. Protein was BSA, polymer was PLA 175 kDa. Ratios of organic/aqueous phase 
ranged from 6.7:1 to 20:1 (v/v). Ratios of protein/polymer ranged from 1:2 to 1:6 (w/w). ↑ = 
increase, ↓ = decrease. *Particle size was shown to initially increase and then decrease in the 
studied range [45]. 
 
 Viscosity 
Electrical 
conductivity 
Particle size 
Loading 
capacity 
Encapsulation 
efficiency 
In vitro 
release 
↑ Organic/aqueous 
phase 
↑ ↓ ↑ ↑ ↑ ↓ 
↑ Protein/polymer  
phase 
↑ Little effect ↑↓* ↓ ↓ ↑ 
 
Matrix use 
 When loading electrosprayed particles into a matrix such as hydrogels, different release 
kinetics may be obtained by varying the gelation time, the concentration of the cross-linking 
agent and particle loading. For example, paclitaxel-loaded PLGA microspheres (12 µm 
average size) loaded in alginate macrobeads (1.61-1.68 mm  average size) provided different 
release kinetics. Although the authors did not show the release profiles of non entrapped 
microspheres, most alginate formulations provided zero-order release kinetics of paclitaxel 
over 60 days reaching over 70% cumulative release for the best formulation (50% 
microsphere loading, 5 min gelation time and 1% CaCl2) [25]. The small burst release 
(maximum of 10%) observed for the 50% microsphere-loaded formulations was reduced 
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when alginate beads were increasingly loaded to 80 and 90% of microspheres. However 
overall kinetics were also reduced reaching a maximum of 50% and 22% cumulative release 
after 60 days for 80 and 90% microsphere-loaded formulations respectively. The extent of 
cross-linking did not show a clear trend, since for the 50%-loaded formulation, extended 
cross-linking resulted in lower release profiles while the opposite was seen for the 80% 
formulation and it was not significantly different for the 90% formulation. This indicates that 
the microsphere loading in the matrix may be a more determinant factor in release kinetics 
than the extent of cross-linking [25].  
 
4.5. Denaturation  
 
Electrospraying remains a process that employs organic solvents and therefore the 
possibility of drug degradation and protein denaturation needs to be assessed and compared 
to traditional encapsulation techniques to prove its superiority. So far, limited studies have 
addressed this issue, nonetheless they present promising results. The techniques generally 
employed are sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), 
Fourier transform infrared (FTIR), ultraviolet (UV), and circular dichroism (CD) 
spectroscopy [43, 51-52, 80].  
In the early stages of denaturation assessment by electrospraying, the model protein BSA 
was directly electrosprayed from an ethanol solution. Structural changes were assessed by 
UV and CD spectroscopy showing that electrospraying of the protein did not result in 
significant structural changes of BSA, particularly at higher concentrations (up to 20 mg/mL) 
[80]. When encapsulating the same protein in PLGA microcapsules, no alteration in the 
secondary structure of BSA was observed as confirmed by comparing the CD spectra of BSA 
before and after release from polymeric microparticles [51]. In a study from Xie and Wang, 
the authors used SDS-PAGE to investigate the protein integrity of BSA released from PLGA 
(50:50) microparticles after 38 days and characterized the secondary nature of BSA by FTIR 
and CD spectroscopy. They found that the released BSA was almost identical to native BSA 
(after 1 day release) and no protein degradation was observed during the 38 days release [43]. 
Although promising progress has been made, more studies are required to assess a greater 
variety of molecules (drugs, growth factors, enzymes, DNA) in contact with various organic 
solvents, and various polymers, since the purity and source of molecule, and the nature of 
polymer can also influence the stability of loaded molecules. Besides, BSA remains a very 
stable protein which is unlikely to suffer from denaturation. Typically, protein denaturation is 
potentially a major problem in encapsulation processes involving organic solvents and it 
needs to be more thoroughly assessed for the electrospraying technique. So far, when 
therapeutically relevant proteins such as IGF-1, PDGF and VEGF were loaded in 
electrosprayed particles, authors discussed the bioactivity of the released proteins by 
performing cell-proliferation assays rather than using the typical assays for the assessment of 
protein degradation (SDS-PAGE, CD, etc.). Since in both studies the released proteins were 
shown to be bioactive, i.e. induced cell proliferation, the authors correlated their results with 
denaturation, concluding that the electrospraying technique was efficient in protecting the 
growth factors from denaturation [47-48]. This approach is a nice start to degradation 
assessment, showing that part of the released proteins was indeed intact; however it remains a 
qualitative assessment and does not conclude quantitatively on potential protein structural 
changes.  
Traditionally, with emulsion techniques, additives such as surfactants, carrier proteins, 
sugars, salts, amino acids and polymers are considered to protect the loaded molecules [102]. 
Hydrophilic additives such as BSA as an excipient [103] and polyethylene glycol (PEG) 
[100, 104-105] have demonstrated good protection of growth factors in traditional emulsion 
techniques. However such use has not yet been seen in electrospraying since there is little 
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focus on denaturation of loaded proteins, where in most studies, loadings, encapsulation 
efficiencies and in vitro release profiles of electrosprayed particles remain the most discussed 
characteristics of these systems. This approach is not ideal when one considers that denatured 
proteins will ultimately not fulfill their intended function, despite whether they have proven 
to be ideally loaded, encapsulated or released. As discussed earlier, bioactivity assessment is 
an indirect way of assessing denaturation, although it does not provide thorough description 
of structure changes of proteins. Therefore, although the denaturation of protein drugs seem 
to be minimal through the electrospraying process, as seen with bioactivity assays, more 
extensive denaturation studies are required. To this end, the use of appropriate additives for 
the electrospraying technique may be identified to fight any potential degradation of 
molecules. To date, only Xie et al. have published the use of Pluronic F-127 as an additive to 
tailor and enhance the protection of BSA in PLGA electrosprayed particles [43].  
Another potential disadvantage of electrospraying is the use of electric fields, since they 
intensify around the highly charged droplets in the course of solvent evaporation. Such high 
fields may induce conformational changes of the bioactive molecule, leading to denaturation 
and thus loss of bioactivity. It was indeed proven that electrospinning of collagen out of 
fluoroalcohols denatured collagen to gelatin due to the presence of high voltage [106]. 
Nevertheless, this hypothesis is counterbalanced in the literature by the fact that, in 
electrospraying, the droplet size is on the micro-to nano-scale, allowing for solvent 
evaporation to occur over milliseconds, which is considered too short to have significant 
effects on denaturation [16]. 
 
4.6. Bioactivity 
 
The bioactivity of electrosprayed molecules was first assessed by electrospraying insulin 
from an acidic water-ethanol solution. Bioactivity was assessed by comparing the insulin 
receptor binding properties from electrospray-processed insulin and control insulin. No 
significant differences were observed and the authors further stated that the electrospraying 
technique was sufficiently „gentle‟ not to hinder the insulin biological activity [16]. 
Progressing towards the bioactivity of molecules encapsulated within a polymeric matrix, 
several types of tests involving different cell lines are presented, according to the type of 
encapsulated molecule: protein, anti-cancer drug, anti-bacterial drug, antibiotic, etc. 
The most commonly used model protein encapsulated in electrosprayed particles is BSA. 
However, BSA‟s bioactivity after encapsulation is rarely studied.  Interestingly, in a study 
from Xie et al., PLGA microparticles were used to encapsulate BSA, however lysozyme was 
used as the “model protein” to study the bioactivity of entrapped molecules, although BSA 
was the focus of all other characterizations in the paper [43]. The concentration of released 
lysozyme from lysozyme-loaded PLGA microparticles was quantified by characterizing the 
rate of lysis of Micrococcus lysodeikticus cells by lysozyme after one day of incubation with 
particles. 92% of bioactivity was calculated and it was stipulated to be much higher than with 
traditional encapsulation methods (30-80%) [43]. In a similar study from the same authors, 
the same assay was used for PLGA microcapsules made by coaxial electrospraying and 
lysozyme bioactivity reached this time 94.6% after in vitro release [51]. Although promising, 
both these studies mainly described the encapsulation of BSA (denaturation, encapsulation 
efficiencies and release) but used lysozyme for depicting bioactivity. This creates a gap in 
characterization since results may not necessarily directly translate from one molecule to the 
other: since BSA (a plasma protein) and lysozyme (an enzyme) have different structures and 
size (66.4 kg/mol and 14.7 kg/mol respectively), thus they may be affected by the 
electrospraying process in a different way, likely leading to different results.  
When encapsulating anti-cancer drugs such as paclitaxel, bioactivity is generally assessed 
by Coumarin-6 (C6) glioma cells (brain tumor cells) inhibition with cell cycling analysis and 
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3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay [27]. In the study from Xie et al., cell viability was hardly affected by particle 
concentration but was significantly decreased with increasing exposure time (1 to 5 days), 
showing a delayed cytotoxic effect of particles, equivalent to Taxol
®
 treatment at day 4 and 5 
only [27]. The same cytotoxicity test was used for electrosprayed PLGA films loaded with 
paclitaxel [29] where a decrease of C6 glioma cell viability compared to unloaded films was 
clearly seen, while an increase in the loading (5 to 30%) showed only a slight decrease in cell 
viability (from around 65% to 52% viability) without being statistically significant. In 
another study from Nie et al. where paclitaxel and suramin were coaxially encapsulated in 
microcapsules, a continued marginal increase in apoptotic activity of C6 glioma cells was 
shown after 9 days, proving the efficiency of the capsule system to deliver anti-cancer agents 
in a sustained way. Interestingly, cellular recovery was observed in free drug treated groups, 
indicative of the limitations of systemic drug administration, providing only short and acute 
exposure due to low terminal half-life of paclitaxel and suramin [30]. In another study the 
same authors showed that apoptotic activity was increased with the delivery systems 
compared to the free Taxol
®
 groups over 9 days. They also found an increased apoptotic 
activity for their co-delivery system compared to single delivery with the combination 
„suramin in the core‟ and „paclitaxel in the shell‟ (S/P) outperforming the opposite 
formulation (P/S). This could be correlated with in vitro release results where the S/P 
formulation released higher doses of drugs compared to the P/S formulation [63]. 
 A similar result was observed by measuring in vitro cellular apoptosis from alginate 
macrobeads containing electrosprayed PLGA microspheres releasing paclitaxel. Although the 
Taxol
®
 control group gave high apoptosis of C6 glioma cells at day 2, it decreased at day 4 
and 6 while beads formulations were giving increased and significantly higher apoptosis over 
time, demonstrating the potential of the delivery system to sustain therapeutic levels of 
paclitaxel [25]. 
When loading antibiotics to treat antibacterial infections such as ampicillin or ripamficin 
in electrosprayed particles, bioactivity can be assessed by measuring the zone of inhibition in 
contact with sensitive bacterial strain such as E. coli DH5α in the case of ampicillin. When 
using such test, the bioactivity of ampicillin released from chitosan particles was proven by a 
similar inhibition zone for loaded particles and for the same amount of free drug [23]. 
However a very small inhibition zone was also observed with unloaded particles, which the 
authors attributed to the inherent antibacterial activity of chitosan. This result may be further 
investigated to ensure the non-cytotoxicity of unloaded particles before loading of any 
therapeutic molecule.  
For tissue regeneration and mainly angiogenesis, when growth factors such as IGF-1, 
PDGF and VEGF were loaded in electrosprayed particles, their bioactivity was respectively 
assessed by a smooth muscle cell (SMC) proliferation assay for IGF-1 [47] and human 
umbilical vein endothelial (HUVEC) cell and lung fibroblasts (LF) proliferation assays for 
VEGF and PDGF respectively [48]. The SMC viability was assessed by a (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and was shown to be 
significantly increased over a 4 week period with exposure of released IGF-1. The results 
showed that the bioactivity of IGF-1 was dependent on: the amount of IGF-1 loaded; the 
amount of PLGA and its molecular weight. Briefly, IGF-1 demonstrated more bioactivity for 
higher PLGA concentration, higher IGF-1 loadings and lower molecular weight PLGA [47]. 
The viability of HUVECs and fibroblasts used for determining the bioactivity of PDGF and 
VEGF was assessed by the PicoGreen dsDNA quantitation kit. The bioactivity of both GFs 
was shown to be high after two days in vitro indicating minimal changes to the proteins 
during the electrospraying process (around 80-90%). Interestingly, bioactivity decreased to 
less than 21% after 21 days, which authors attributed to the in vitro conditions that were too 
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harsh for growth factors, prone to oxidation and pH dependent deamidation in the in vitro 
context [48].  
When encapsulating therapeutic molecules in polymeric devices, the use of PEG as an 
additive is shown to affect the release profiles, but also known to protect the bioactivity of 
encapsulated molecules. PEG has not been used yet in electrosprayed particles, although 
other polymeric devices have proven its benefits. For instance Morita et al. indicated that co-
lyophilization of PEG and horseradish peroxidase before exposure to organic solvents 
increased the retention of bioactivity [104]. Johnson et al. confirmed this theory by showing 
significantly more retention of nerve GF (NGF) when PEG was co-lyophilized before 
encapsulation in PLGA discs [100]. Co-lyophilization of PEG with therapeutic molecules 
may thus be considered in electrospraying when the solid dispersion method is used for 
enhanced bioactivity. 
 
4.7. In vivo performance 
 
Most studies on electrosprayed particles loaded with therapeutic molecules are done 
within an in vitro context. This approach is very important so that parameters can be tailored 
and optimized in the first instance, before the use of animals to further validate the optimized 
formulations. However in vivo data remains essential for translation of electrosprayed 
particles loaded with therapeutic molecules to the clinic. Owing to electrospraying, as applied 
to biological loadings, being in its relative infancy, only limited in vivo data is currently 
available, although these studies do show promising results.  
Most in vivo studies involve the assessment of tumor treatment by sustained release of 
anti-cancer agents such as paclitaxel and suramin [25-26, 63]. In the study from Naraharisetti 
et al. for instance, 10 and 20% (w/w) of paclitaxel were loaded in PLGA 50:50 particles by 
electrospraying from a DCM solution, providing final microparticles of 15.0 µm in diameter 
within a narrow size distribution of 1.7 µm [26]. C6 glioma cells were inoculated 
subcutaneously to BALB/c nude mice and loaded particles were injected to the tumor in two 
doses on day 14 and 28 at 0.5 mg paclitaxel/injection. A control injection of 1 mg of 
commercial paclitaxel (Taxol
®
) was injected only at day 14 for comparison. All the groups 
showed improved tumor suppression over the placebo control and cytotoxicity of the 
microparticles was evident in the analysis by H&E staining of the tumor tissue when 
compared with the placebo and commercial Taxol
®
 control. Both in vitro release profiles 
from 10 and 20%-loaded particles showed similar release kinetics, with an initial burst 
release over the first 2 days before sustained release for the further 28 days, with only the 
burst being higher for the 20% formulation. Such burst release was shown to be more 
effective in treating the tumor since the 10% drug-loaded group performed poorly compared 
to the 20% drug-loaded group and the Taxol
®
 control (10% drug-loaded group had to be 
sacrificed at 14 days due to excessive tumor volume, and a second injection at 28 days could 
not therefore be performed) [26].  
In a similar study from Ranganath et al. (Fig. 7A-C), monodisperse paclitaxel-loaded 
PLGA microspheres were obtained by electrospraying, with an average size of 11.79±2.79 
µm and a smooth, spherical morphology [25]. The loaded microspheres were further loaded 
in alginate macrobeads (1.61-1.68 mm average size) (Fig. 7A) and presented various release 
profiles according to gelation time, concentration of the cross-linking agent and microsphere 
loading (Fig. 7B). Two formulations were selected to be implanted in subcutaneous C6 
glioma tumor in mice and both showed smaller tumors in comparison to the blank after 21 
days. However, only the formulation with medium cross-linking (M80) was able to 
demonstrate significantly smaller tumors compared to the free Taxol
®
 group, while the highly 
cross-linked formulation (H80) gave lower tumor formation but not significantly (Fig. 7C). 
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Importantly these results were different from the in vitro results where H80 released more 
paclitaxel than M80 and in a slightly more rapid manner [25].   
Still within the context of brain tumor treatment, Nie et al. prepared electrosprayed 
core/shell capsules by coaxial electrospraying of PLLA for the core and PLGA 50:50 for the 
shell (Fig. 7D-G) [63]. They loaded simultaneously both paclitaxel and suramin, with either 
paclitaxel in the core and suramin in the shell (P/S formulation) which provided a sequential 
release, or the opposite (S/P formulation), which provided a release in parallel (Fig. 7F). 
Interestingly, in vitro data showed that the highest apoptotic activity was obtained for the S/P 
formulation over 9 days. However when looking at the in vivo results (subcutaneous 
inoculation of U87 MG-luc2 xenograft in BALB/c nude mice), the P/S formulation was best 
in inhibiting growth of brain tumors after 21 days (Fig. 7G). The authors deducted that the 
presence of a higher released dose of suramin at the early stage efficiently prevented the 
excess growth of tumor cells while a subsequent controlled and sustainable release of 
paclitaxel could induce the apoptosis of tumor cells continuously [63]. 
The results from both these studies underline the versatility of the electrospraying 
technique being able to generate different release profiles according to the processing 
parameters (in these cases being the drug loading [26], the extent of matrix cross-linking [25] 
and the location of loaded drugs [63]) and generating different in vivo results. Importantly, an 
initial burst release before the onset of a linear release was shown to be more effective in 
tumor suppression and provided important feedback for tailoring in vitro release profiles, 
showing that zero-order release kinetics are not always desired for efficient therapeutic effect 
[26]. The importance of undergoing in vivo studies is also shown to be paramount when 
looking at the study from Ranganath et al. and Nie et al., where in vivo results may give 
different results to what would be extrapolated from the in vitro data [25, 63].  
  
 
 
Fig. 7.  (A) Representative SEM image of paclitaxel-loaded PLGA microspheres (large arrow) 
entrapped in an alginate matrix (small arrow). Scale bar is 200 µm. (B) In vitro release of 
paclitaxel from different formulations of microspheres entrapped in the alginate matrix. L80, 
M80 and H80 correspond to different degrees of cross-linking (low, medium, high) with 1, 
5, 15 min gelation time and 0.5, 1, 2% (w/w) of CaCl2 concentration, respectively. (C) In 
vivo subcutaneous C6 tumor volume profiles of mice treated with different groups for 21 
days (n=5). The control group had no beads and no drug; the placebo group was implanted 
with alginate macrobeads but no drug; the Taxol
®
 group received an injection of 180 µg of 
Taxol
®
 directly in the tumor mass; and animals in the H80 and M80 were implanted with 2 
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mg of alginate beads loaded with microspheres containing an average amount of 162 µg of 
paclitaxel per animal [25]. (D-E) Representative SEM images of PLLA/PLGA capsules 
loaded with (D) P/S formulation (paclitaxel (PTX) in the core and suramin (SRM) in the 
shell) and (E) S/P formulation (SRM in the shell and PTX in the core). Scale bar is 100 µm. 
(F) In vitro release of PTX and SRM from P/S and S/P formulations. (G) In vivo 
subcutaneous U87 MG-luc2 tumor progression profile over the period of treatment 
measured as normalized bioluminescence intensity (n=5). The blank group received no 
injection of drug; the placebo group was implanted with blank particles; the S/O group 
received particles loaded with only suramin in the core while particles were loaded only 
with paclitaxel in the P/O group [63]. Adapted from [25, 63] with permission. 2009 Springer 
[25]; 2010 Elsevier Science Ltd. [63]. 
 
5.  The use of electrosprayed particles in electrospun scaffolds 
 
5.1. Electrospun nanofibers and drug delivery 
 
Amongst the many scaffolds that have been generated to date in the field of tissue 
engineering (TE), some of the most promising are the scaffolds produced which comprise 
nanofiber structures [107-108]. The nanoscale could be argued as being the most realistic 
scale to approach when mimicking the architecture of natural tissues. Nanofiber scaffolds are 
distinctive compared to scaffolds at the micro- or macro-scale owing to their similarity to 
natural extracellular matrices, like collagens, which are the major protein components of 
many tissues including skin, tendon, ligament and bone. Collagen is characterized by a 
fibrillar structure shown to enhance cell attachment, proliferation and differentiation in tissue 
culture [108]. For this reason, engineers aim to mimic its structure whilst fabricating 
engineered tissues to closely resemble the native tissues. In addition, the high surface to 
volume ratio of nanofiber scaffolds is highly favorable for drug loading, while its high 
porosity and interconnected pores facilitates nutrient and waste exchange during tissue 
regeneration. These scaffolds can also be further modified by various 3D surface 
modification techniques to incorporate other valuable features of the extracellular matrix 
[108]. Nanofiber scaffolds are studied in various areas of TE: in neural TE, where uniaxially 
aligned nanofibers can be used to guide the growth of neurons [109], in bone TE, where 
nanofibers may be mixed with hydroxyapatite (HA) to mimic the bone extracellular matrix 
which is mainly composed of collagen and HA [109-110], and in cartilage TE, where 
nanofiber meshes can support cell spreading and growth of chondrocytes [110]. 
Three main techniques have recently emerged in the production of nanofibers: 
electrospinning, phase separation and self-assembly. The two first techniques mainly use 
polymeric materials due to their ease of processability and capacity to provide a large variety 
of cost-effective materials. All methods can produce nanofibers, even though electrospinning 
has been shown to generate larger diameter nanofibers on the upper end of the nano-range of 
natural collagen, rather considered to be submicron [107]. Electrospinning remains the most 
widely used technique for production of nanofibers, due to numerous advantages when 
compared to the other techniques: it is simple, cost effective, reproducible and versatile: a 
wide range of natural and synthetic polymer solutions can be used (collagen, silk fibroin, 
PCL, PLGA, polyurethane (PU), poly(methyl methacrylate)(PMMA), etc.) and the method 
allows for control of fiber diameter and alignment [107-108, 110-111] (Examples include 30-
120 nm for silk fibroin [112], 250-800 nm for PCL [113-114] and 200-1000 nm for PLGA 
[115]). 
Electrospinning is an electrohydrodynamic variant of electrospraying which uses identical 
apparatus. Compared to electrospraying, solution electrospinning requires polymer solutions 
with higher viscosity, which can be obtained by using higher molecular weights or most 
generally higher polymer concentrations that ensure at least 2.5 entanglements per polymer 
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chain [78]. The regime used for electrospinning must be in the semi-dilute highly entangled 
regime where ratio C > 3Cov which can be up to 10Cov for obtaining uniform fibers, and 
which depends on the molecular weight distribution of the polymer chains in solution [79]. 
Nanofibers have been investigated as drug delivery vehicles as well, where drugs could be 
dissolved or dispersed in the polymer solution before electrospinning [116] or by using 
coaxial electrospinning wherein a secondary polymer solution containing the biomolecules is 
electrospun within the core of the forming nanofiber [99, 117]. The tissue-conductive only 
scaffold then becomes a tissue-inductive scaffold by releasing bioactive agents capable of 
inducing specific tissue treatment. Nanofiber scaffolds applied to drug delivery have 
predominantly been focused on the loading of antibiotics and anti-cancer agents [118], and 
there have been several reports regarding the incorporation of growth factors into these 
scaffolds [99, 119-123]. More details on electrospinning and drug delivery can be found to 
review by Sill and von Recum [124]. 
Although direct incorporation of drugs into nanofibers seems promising, there is presently 
a lack of characterization of these systems. For instance some studies have been done in vitro, 
while the understanding of scaffold behavior and effectiveness in vivo is essential for clinical 
applicability of these devices [118]. In addition, drawbacks such as low reproducibility do not 
allow sufficient control over drug distribution and thus insufficient control of the release 
profiles. This impairs both reproducible pharmacokinetics and pharmacodynamics. Drug 
aggregation in solution is another issue which can lead to denaturation and non-homogeneous 
distribution within the scaffold after processing [120, 123]. Importantly, when the scaffold is 
responsible for load bearing and drug delivery simultaneously, direct incorporation of drug 
within the nanofibers may have adverse effects on the mechanical properties of the scaffold 
[125]. This is particularly important for bone applications where bioactive agents such as 
growth factors must be released when the load-bearing implant can still perform its function 
[126]. For instance, when NGF was directly incorporated into the electrospinning solution, it 
resulted in a loss of control of the mesh properties and in a low loading efficiency (about 
3x10
-4
%), which was attributed to differences in charge densities between the GFs and 
polymer resulting in a chaotic and instable jet [123].  Based on these factors, it may be 
concluded that the loading of bioactive agents in nanofibers may not be ideal for controlled 
drug delivery. 
 
5.2. Electrospun nanofibers and particles for drug delivery 
 
The use of loaded microparticles in nanofiber scaffolds was introduced as a response to 
the drawback provided by direct encapsulation in nanofibers, where both scaffold properties 
and delivery requirements were difficult to attain [127]. Separating the drug of interest from 
the scaffold permits the use of a different material for encapsulation, which allows enhanced 
properties for the intended function of both the scaffold and drug reservoir. Among many 
others, the scaffold material requires higher mechanical properties, slower degradation and 
interconnected structures for cell infiltration, while the microparticles containing the drug 
need to provide positive interactions with the drug for high loading and enhanced protection 
from the environment, along with tunable degradation for the tailoring of release profiles. 
The use of such composites can enhance encapsulation efficiencies but also allows control 
over drug distribution within the scaffold, by providing different gradients or loading patterns 
within the scaffold. Importantly, in direct encapsulation in scaffolds, loading is often limited 
to only one component [30] since bioactive agents can aggregate and denature after contact 
with each other when multiple loading is attempted within the same scaffold material [128]. 
However, some applications such as tissue regeneration or cancer therapy require the action 
of more than one type of drug or protein being delivered in various fashions (linear, pulsatile, 
delayed, burst) according to a programmed cascade triggered by cells for a specific treatment 
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[3]. For instance in tissue regeneration, the formation of a mature vascular network is known 
to involve, among others, VEGF-165 and PDGF, both with distinct temporal actions [129]. 
By using separate populations of microspheres, independent bio-agents can be loaded, whose 
release profiles are tuned with the particle characteristics, without altering the scaffold 
characteristics, thus meeting both the delivery and scaffold requirements.  
 
5.2.1. Loaded particles in electrospun nanofibers 
 
The incorporation of loaded nano/microparticles into electrospun scaffolds can be 
achieved by using a drug emulsion (Fig. 8A) [130-131] or pre-formed microspheres (Fig. 8B-
D) [125, 132] within the electrospinning solution. In the first case, an aqueous solution 
containing a bioactive agent is mixed with an organic polymer solution, also known as 
emulsion electrospinning, providing aqueous reservoirs within electrospun nanofibers. Dong 
et al. used this technique to incorporate two distinct populations of nanospheres within fibers, 
and presented their findings in a short communication (Fig. 8B-C) [131]. They first loaded 
PVA particles with BSA or epidermal growth factor (EGF) by a single emulsion process. 
This involved emulsifying the PVA solution containing BSA or EGF, followed by hardening 
of the formed nanoparticles, before incorporating in a polyurethane (PU) solution and further 
electrospinning (Fig. 8B). In terms of parameters, increasing the concentration of PVA from 
1 wt% to 5 wt% in the PU solution led to the formation of larger PVA particles, with an 
average diameter increasing from 200 nm to 300 nm. The fibers had an average diameter of 2 
µm. The authors managed to show the distinct populations of nanospheres within the fibers 
by labeling BSA and EGF with fluorescent dyes (Fig. 8C). They commented on the 
opportunity to control the release of multiple compounds, potentially at distinct rates, but did 
not provide more details. No information was given pertaining to loading and efficiency 
capacities, bioactivity of released molecules or release profiles [131].  
 
 
 
Fig. 8.  Incorporation of loaded nano/microparticles into nanofibers by using (A) drug emulsions 
[130] and (B-D) pre-formed microspheres [125, 131]. (A) Schematic overview over the four 
major steps of microencapsulation in fibers by emulsion electrospinning [130]. (B) 
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Schematic illustration of the preparation of polyurethane electrospun fibers containing two 
distinct populations of nanoparticles. (C) Overlay of fluorescence image of polyurethane 
fibers containing PVA/EGF-AF488 and PVA/BSA-TR particles when excited with blue 
light with fluorescence image when excited with green light. Scale bar is 20 µm [131]. (D) 
Preparation of composite scaffolds through a sacrificial PEO fiber fraction coupled with a 
stable PCL fiber fraction (Pre-wash). With PEO dissolution (Post-wash), microspheres 
remained entrapped within the PCL network [125]. Adapted from [125, 130-131] with 
permission. 2006 American Chemical Society [130]; 2009 John Wiley and Sons [131]; 2010 
Elsevier Science Ltd. [125]. 
 
More consistently, Qi et al. formed loaded PLLA nanofibers by adding PLLA in an 
emulsion of calcium (Ca)-alginate microspheres containing BSA, providing homogeneous 
beads-in-string structures after electrospinning [130]. Although microspheres had larger 
diameters than fibers, they were found embedded within the fibers (Fig. 9B). The authors 
supposed that when the emulsion flew through the capillary, due to the rapid jet elongation, 
the dispersed phase accumulated in the centre of the liquid along the fluid direction, allowing 
microspheres to settle into fibers rather than on surfaces. However, an increase in the 
electrospinning voltage, above 20kV, led to inferior morphology with a decrease in fiber 
diameter and microspheres transforming into spindles. Although the final cumulative release 
of microspheres in nanofibers was slightly decreased compared to blank microspheres (less 
than 10% difference), the microspheres from the composite provided a lower initial burst 
release as well as a more sustained release over the period of study (120 hours) as seen in Fig. 
9C [130]. Although the delivery characteristics of this system were promising, no information 
was given on the scaffold properties and performance after addition of microspheres.  
In a similar study, chitosan nanoparticles encapsulating naproxen and rhodamine B 
separately were made by ionic gelation and mixed into a PCL electrospinning solution [132]. 
After electrospinning, nanoparticles were embedded in the fibers and release rates from fibers 
were slower than bare nanoparticles. Different release kinetics could be obtained by 
incorporating the raw molecule or incorporating the chitosan nanoparticles containing the 
molecule in the PCL solution. However, less final cumulative release was observed in the 
latter case for loading of rhodamine B (18% from nanoparticles in fibers versus 70% from 
fibers after 70 hours) [132]. 
In addition to the emulsion method and direct incorporation of particles into the 
electrospinning solution, an interesting technique was recently proposed, using a co-spinning 
process of a sacrificial polymer (polyethylene oxide (PEO)) solution containing preformed 
PLGA microspheres, with a PCL solution [125]. Upon hydration, PEO was removed, leaving 
the microspheres entrapped between the PCL nanofibers (Fig. 8D). The use of sacrificial 
fibers in electrospinning was previously shown to increase scaffold porosity and cell 
infiltration by the same authors [133]. Using this method for incorporating microspheres was 
aimed at mitigating any changes to the scaffold properties, an issue with direct encapsulation 
into nanofibers [99]. In order to assess the mechanical properties of scaffolds, polystyrene 
microspheres (15.7 µm in diameter) were used as a model microsphere (since authors argued 
that PLGA microspheres would have dissolved in the solvent used for electrospinning) and 
entrapped either within or between the nanofibers, for mechanical comparison. When 
microspheres were included in PCL, it was shown that both the stiffness and modulus 
decreased with increasing microsphere density. However, when the microspheres where 
entrapped between the fibers, no change in stiffness was observed for any density, and the 
modulus were equivalent but only for low microsphere densities (0.05 mg of 
microspheres/mL of solution). In terms of loaded biomolecules, BSA and chondroitin 
sulphate (CS) were used for encapsulation in PLGA microspheres through a w/o/w double 
emulsion. Very low encapsulation efficiencies were obtained; 13% and 11% respectively. 
Release kinetics were independent from one another and comparable to composites 
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containing only the single populations. A slightly more sustained release profile was 
observed for CS in the scaffold compared to free microspheres (25 days, maximum release of 
more than 60% in all cases), while the maximum release was reached after only 5 days for 
BSA with about 20% for free microspheres and 10% for microspheres within the scaffold 
(Fig. 9D-F)) [125].  
All these studies underline the increasing interest for incorporating particles in electrospun 
scaffolds, although release profiles are not yet optimal and their effects on cells in both the in 
vitro and in vivo environments remain to be addressed, along with the characterization of 
mechanical properties of scaffolds after incorporation of loaded particles.  
 
 
 
Fig. 9.  Morphology and release profiles of loaded nano/microparticles embedded in nanofiber 
scaffolds by using (A-C) drug emulsions [130] and (D-F) pre-formed microspheres [125]. 
(A) SEM micrograph of electrospun PLLA fibers containing pre-made polystyrene 
microspheres. Scale bar is 2.5 µm (B) SEM micrograph of electrospun PLLA fibers 
containing Ca-alginate microspheres formed by w/o emulsion. Scale bar is 10 µm. (C) 
Release profiles of BSA from: Ca-alginate microspheres (diamonds); fibers shown in B, 
made at 15kV (squares); fibers with spindle particles corresponding to electrospinning at 
20kV (triangles) [130]. (D) SEM micrograph of composite scaffolds made through a 
sacrificial PEO fiber fraction containing BSA- and CS-loaded microspheres coupled with a 
stable PCL fiber fraction. (E) Release of BSA or CS from PLGA microspheres. (K) Release 
of both BSA and CS from the single composite system containing both BSA and CS 
microspheres at a 1:1 ratio [125]. Adapted from [125, 130] with permission. 2006 American 
Chemical Society [130]; 2010 Elsevier Science Ltd. [125]. 
 
5.2.2. Multiple  electrospraying/electrospinning 
 
5.2.2.1. Concept 
As explained previously, the electrospinning/electrospraying processes use simple 
apparatus consisting of syringe pumps, collectors and external voltage supplies, and thus they 
can be easily manipulated to fit specific requirements (horizontal, vertical, or angled setups). 
For this reason, these apparatus may be easily used in combination, for the production of 
composites with an increased number of properties. Early attempts to electrospray whilst 
electrospinning consisted of side-by-side capillaries and a flat collector moving on an x-y 
stage [134].  Although the scaffolds yielded were 100 µm in thickness after 45 min, the area 
of stream convergence was so small that non-uniform integration was obtained. The authors 
attributed this problem to a stream repulsion effect from Coulombic forces, which they 
limited by locating the nozzles perpendicular to one another and using a rotating mandrel 
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translating on its axis. Stream repulsion was minimized and the combination of rotation and 
translation of the mandrel target provided an ideal integration of both components 
(electrosprayed smooth muscle cells and poly(ester urethane) urea (PEUU) fibers in this 
case). Using this configuration, 5x5 cm construct sheets ranging from 300 to 500 nm in 
thickness were created and scaffold thickness could be controlled by adjusting polymer feed 
rate or fabrication time. The authors concluded that this setup may find other applications in 
the future as a means to fabricate more uniform composite scaffolds by electrospinning 
multiple materials or introducing drug-laden microspheres between fibers, a setup which has 
indeed been used in consecutive years for either multiple electrospinning or simultaneous 
electrospraying/electrospinning [134].   
 
5.2.2.2. Multiple electrospinning 
Compared with single electrospinning, more versatility in properties can be achieved with 
multiple electrospinning. The drug delivery characteristic can indeed be effectively coupled 
with desired mechanical properties. This was obtained, for example, by simultaneously 
electrospinning PLGA fibers loaded with tetracycline hydrochloride (TET), for antibacterial 
activity, with PEUU, that maintain the required elastomeric properties [135]. The use of a 
rotating mandrel for collecting these constructs is the best approach in multiple 
electrospinning. It allows aligned fibers, a configuration highly desirable in tissue 
engineering, since it mimics some of the fibrous musculoskeletal tissues, like tendons and 
ligaments. Although fewer studies on multiple electrospraying/electrospinning are available, 
they also use a rotating mandrel collector and most of these studies face similar issues 
relating to this mandrel approach.  
Fundamentally, the main limitation in aligned fibers obtained by collection onto a rotating 
mandrel is the high density fiber packing, since fibers are drawn in parallel to one another. 
This becomes an issue for cellular infiltration, where in most cases, cellular and tissue 
formation are often limited to the surface of the electrospun construct, impairing the 
necessary cell growth within the central architecture of the construct [48]. The use of a 
second electrospinning apparatus was proposed for simultaneous electrospinning of 
sacrificial fibers that, once they are removed from the scaffold, confer an increased porosity, 
beneficial for cell infiltration, while maintaining the anisotropy of the scaffold. To this end, 
PCL and PEO were co-electrospun onto a rotating mandrel, followed by dissolution of PEO 
into water after production (Fig. 10B) [133]. Importantly, cell infiltration and distribution 
after three weeks in culture increased in the starting sacrificial fraction when scaffolds were 
seeded with mesenchymal stem cells [133]. On the other hand, limited cell infiltration was 
reported when a PCL/collagen blend was co-spun with PEO [136]. Certainly the 
electrospinning parameters have a great influence in the fiber deposition and fiber 
characteristics and must be optimized for effective improvement in cell infiltration. Another 
approach to improve cell infiltration was proposed which involved simultaneously 
electrospinning microfibers and nanofibers, obtained by melt and solution electrospinning, 
respectively (Fig. 10A). Microfibers increased the porosity of scaffolds to facilitate cellular 
infiltration and nanofibers gave an enhanced effect on cell attachment and growth due to the 
nanoscale features (Fig. 10C-E). The so-produced PLGA composite scaffolds provided 
significantly higher attachment and spreading of both human epidermal keratinocytes and 
fibroblasts (Fig. 10F-H) [137].  
Another drawback of electrospun fibers from synthetic polymers, which may be overcome 
by multiple electrospinning, is the lack of biological recognition. For some applications 
however, such as vascular grafts, a cell-responsive surface is paramount. This has been 
achieved by simultaneously electrospinning PCL and silk fibroin, for their respective 
mechanical and cell-conducive properties, onto a rotating mandrel, conferring anisotropic 
properties as well [138]. More than a simple overlapping of nanofibers, double 
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electrospinning provided a high integration of both types of fibers and the change of mandrel 
rotation speed may render the anisotropy tunable. This may be kept in mind when optimizing 
the electrosprayed/electrospun constructs. 
 
 
 
Fig. 10. Multiple electrospinning. Schematic of (A) co-solution/melt electrospinning on a rotating 
mandrel [137] and (B) photo of co-solution electrospinning apparatus [133]. (C-E) SEM 
images of three types of nano-/microfiber composite scaffolds: (C) nanoparticle/microfiber 
scaffold for 1wt% solution of the nano-component, (D) beaded nanofiber/microfiber 
scaffold for 9wt%, (E) nanofiber/microfiber scaffold for 10 wt%. Scale bar is 20 µm. (F) 
Cell numbers of human epidermal keratinocytes (NHEK) and human epidermal fibroblasts 
(NHEF) that adhered to two types of scaffolds after 1h (means±SD, n=4). (G-H) 
Micrographs of NHEF in (G) PLGA microfiber scaffold and (H) PLGA nano-/microfiber 
scaffold (10/90) [137]. Adapted from [133, 137] with permission. 2010, 2008 Elsevier 
Science Ltd. 
 
5.2.2.3. Applications of multiple electrospraying/electrospinning 
The multiple electrospinning devices have recently proven quite promising in enhancing 
the typical properties obtained with single electrospinning. In a similar fashion but different 
scope, the association of electrospinning with electrospraying was proposed to provide a 3D 
structural construct of nanofibers embedded with electrosprayed particles for varied 
applications such as drug delivery, coatings or cellularization of the constructs. Such a 
simultaneous process would allow the composite production in a single step sequence and 
permit a better integration of particles within the scaffold. Due to the versatility of both 
processes, several types of scaffolds could be easily and quickly achieved while adding extra 
properties without affecting the essential properties required for scaffolds. 
 
5.2.2.3.1. Drug delivery 
The application of coaxial electrospraying technique in association with electrospinning 
applied to drug delivery was first reported in 2009 by Wang et al. and shown in Fig. 11 [47]. 
They created a soft tissue-engineered construct (TEC) with anisotropic structure, able to 
deliver growth factors for the survival of cells which were often subjected to hypoxia and a 
nutrient starvation microenvironment in the context of TECs [139]. The co-spinning 
technique enabled simultaneous electrospinning of polyurethaneurea (PUU) nanofibers and 
electrosprayed PLGA microcapsules of an IGF-1 gelatin solution, obtaining the direct 
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assembly of a scaffold onto a rotating mandrel collector (Fig. 11A). Results showed that the 
release profile and bioactivity of IGF-1 were dependent on: the amount of IGF-1 loaded 
(tested with 50 and 150 µg/mL); the amount of PLGA (tested with 5 and 10 wt%) and the 
molecular weight (tested with high MW (40-75 kDa) and low MW (5-15 kDa)). The release 
profile was triphasic with an initial burst release attributed to the imperfect core-shell 
structure of the microcapsule (Fig. 11E). It was hypothesized that during the travel of the 
microcapsules toward the collector, the inner part of the shell may have solidified slower than 
the outer part, allowing the leakage of the aqueous IGF-1 into the shell, becoming trapped 
there. The increased release occurring after 3 weeks was attributed to the release of 
accumulated acid from PLGA bulk, creating pores that allowed the encapsulated IGF-1 to 
quickly diffuse out. Bioactivity was maintained over the 4-week study period and the cell 
growth on all loaded scaffolds was assessed in vitro for a 7-day culture period under normal 
conditions and under hypoxia/nutrient starvation conditions with a MTT assay (Fig. 11F). 
The authors stated that the loaded scaffolds were able to significantly enhance cell growth at 
day 7 in both types of conditions. However, by correlating these results with the release 
results observed from day 7 to day 21 day, where the IGF-1 release is almost inexistent, it 
may have been expected that cell survival would decrease after day 7. The authors also 
performed mechanical studies on the scaffolds and observed that the incorporation of PLGA 
microspheres did not significantly alter tensile strength, modulus and elongation break at the 
perpendicular direction, while it did in the alignment direction, which may be a potential 
concern. However mechanical properties at the perpendicular direction were very weak 
compared to those at the alignment direction, before and after incorporation of microspheres, 
which may be why incorporation did not alter significantly the mechanical properties at the 
perpendicular direction [47].  
 
 
 
Fig. 11. (A) One-step fabrication of protein loaded microcapsules and nanofiber scaffolds by 
simultaneous coaxial electrospraying/electrospinning techniques. (B-D) Structure of the 
fabricated microcapsules. FITC-labeled BSA was added into the protein solution, and 
rhodamine-B was loaded into the PLGA solution before fabrication. The resulting 
microcapsule showed: (D) a core-shell structure with (B) protein solution as the core and (C) 
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PLGA as the shell. Scale bars are 2 µm. (E) IGF-1 release kinetics from scaffolds fabricated 
with different PLGA concentration and viscosity and IGF-1 loading at 37 °C. (F) Effect of 
IGF-1 loading on MSC survival under hypoxia/nutrient starvation conditions. MSCs were 
cultured for 1 day under normal culture conditions (21% O2, 5% O2, and 20% fetal bovine 
serum (FBS)) followed by 6 days under hypoxia/nutrient starvation conditions (5% O2, 5% 
CO2, and 1% FBS). (G) Surface morphologies of scaffolds embedded with loaded 
microcapsules. Abbreviations: HV: 40-75kDa PLGA, LV: 5-15kDA PLGA, HV0: scaffolds 
with no microspheres, HV5-50: 5%PLGA-50µg/mL IGF-1, HV10-50: 10%PLGA-50µg/mL 
IGF-1, HV10-150: 10%PLGA-150µg/mL IGF-1, LV10-50: 10%PLGA-50µg/mL IGF-1. 
Adapted from [47] with permission. 2009 American Chemical Society. 
     
5.2.2.3.2. Other applications 
Coating 
A clear advantage in simultaneous electrospraying and electrospinning can be found when 
the application is coating of nanofibers. This is achieved by electrospraying of hydrogels as 
well as non-polymeric particles, such as metal oxide nanoparticles, ceramics, or even cells. 
Using a simultaneous device for coating was first of all shown to be more effective as 
compared to electrospinning and electrospraying in sequence. In a comparative study, 
Jaworek et al. assessed the merits of simultaneous electrospraying during the electrospinning 
process against electrospraying onto the same rotating drum after electrospinning was 
completed and electrospraying onto the electrospun mat removed from the drum and placed 
onto a heated table [140]. Metal oxide nanoparticles such as TiO2, MgO and Al2O3 (20-100 
nm size) were deposited on poly(vinyl chloride) (PVC), polysulfone (PSU) or nylon 
nanofibers of a maximum diameter of 500 nm. The authors observed that the simultaneous 
process produced particle coating with lower density, but particles were distributed more 
uniformly between fiber layers, an advantage for homogenous coating. Post-spinning 
deposition allowed production of denser layers, but the particles were mainly deposited on 
the mat surface, with only minor penetration into the mat while the post-spraying as a 
separate process gave denser coating. However, in this latter case, the coated surface was 
limited to the base of the spray plume that required scanning deposition onto the mat in order 
to cover larger areas [140]. 
Bone tissue engineering 
The simultaneous process was used for several studies requiring coating of fibers, due to a 
need for homogeneous coating. For instance in bone tissue engineering, electrospun 
nanofibers can mimic the composite nature of bone but lack the osteoconductive property, 
which may be counterbalanced by using a blend of hydroxyapatite (HA), the mineral 
component of bone. However, blending HA with the nanofiber material may mask the 
osteoinductive property of HA since the particles are completely embedded inside the 
polymer fibers. Therefore, an electrosprayed coating of HA on nanofibers was proposed to 
create a better environment for growth and mineralization of bone cells. A poly(L-lactic 
acid)-co-polycaprolactone (PLACL)/gelatin blend was spun along with a HA methanol 
solution on a rotating mandrel and the resulting properties were compared with direct 
blending of HA in the polymer solution [141]. The electrospun fibers presenting 
electrosprayed HA particles showed better cell proliferation, enhanced mineralization and 
alkaline phosphatase activity (ALP). This was due to the exposure of HA to the cells which 
gave them the necessary cues to start to lay down bone matrix, but it also 
enhanced/roughened surface topography which is preferential for cell adhesion. Mechanical 
properties were also superior to the blend, collectively proving that electrospraying of HA in 
combination with electrospinning of nanofibers produced suitable osteoconductive scaffolds 
for bone tissue regeneration [141]. The same authors also used this process to coat 
electrospun gelatin only with HA, followed by cross-linking with 50% glutaraldehyde 
solutions, whose cytotoxic effect was negated by washing and drying of the scaffolds. Results 
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were compared with electrospun HA/Gelatin nanofibers of different HA/Gelatin ratios. 
Electrospray-coated nanofibers had a higher pore size and porosity than blended nanofibers, 
as well as larger fiber diameters. Similarly to the previous study, proliferation and ALP 
activity were significantly higher for electrospray-coated nanofibers at 5, 10 and 15 days of 
culture, again due to the complete exposure of HA on the surface of nanofibers. Cross-linking 
was found to confer better stability and mechanical properties than for non-cross-linked 
scaffolds with a tensile strength of 2.7 MPa and a strain at break of 41.5% which are close to 
suitable values for guided bone tissue regeneration [142].  
Cell infiltration and vascularization 
Co-spinning has also been employed for coating electrospun PCL/collagen microfibers 
with electrosprayed Heprasil™, a synthetic hydrogel comprising chemically modified 
hyaluronic acid (HyA) and heparin as an attractive template for cells [136]. By comparing 
only microfibers with nanofibers, better cell infiltration was shown for microfibers. Technical 
considerations included the size of the mandrel used during the co-spinning process with 0.8, 
1.4 and 1.7 cm diameter leading to a 20, 30 and 70% Heprasil collection efficiency 
respectively. As expected, larger mandrels were able to capture the hydrogel droplets more 
efficiently and 1.7 cm was further used to limit losses. Heprasil was loaded with 
AlexaFluor488-labeled BSA, allowing visualization of the random dispersion of Heprasil 
regions within the composite. Cell infiltration in Heprasil-coated PCL/collagen microfibers 
was significantly higher than uncoated fibers, reaching more than 200 µm compared to 50 
µm respectively, after 10 day culture with human foetal osteoblasts. The authors stated that 
the inclusion of Heprasil regions within the mesh created a reduction in the volume density of 
fibers and created compartments of hydrogel for cells to further infiltrate [136].  
A prospective advantage of co-deposition of hydrogel is also the loading of bioactive 
molecules into the composite. Indeed the same authors further used their device to load 
angiogenic factors (VEGF and PDGF), in order to recapitulate the vascular system essential 
in all tissue-engineered constructs [48], which is often hard to achieve (Fig. 12B-F). They 
loaded the growth factors in the Heprasil hydrogel mix which was further electrosprayed 
simultaneously with electrospinning of the PCL/collagen blend microfibers, obtaining 200 
ng/cm² of growth factors for a 32 cm² area of PCL/collagen-Heprasil co-deposition (Fig. 
12B). The use of a co-culture assay of human umbilical vein endothelial (HUVEC) cells and 
lung fibroblasts (LF) with sequential seeding of LF followed by HUVEC permitted the 
infiltration of cells in the mesh with a HUVEC:LF ratio 1:5 being the most satisfactory, while 
seeding alone of HUVEC or higher HUVEC:LF ratios did not yield favorable results. Cells 
also exhibited more physiological morphologies as compared to conventional tissue culture 
plastic, reflecting a more physiological cellular state that ultimately influence cellular 
function and behavior. In terms of release profiles, a burst release followed by sustained 
release was observed for both GFs with approximately 48% and 30% of the total loaded 
VEGF and PDGF, respectively, being released after 5 weeks (Fig. 12D), while bioactivity of 
both GFs constantly decreased from around 80-90% bioactivity after two days in vitro to 1-
20% after 21 days, which authors explained by VEGF in particular being susceptible to pH 
dependent deamidation and oxidation in vitro (Fig. 12E). Importantly cell penetration after 14 
days of co-culture was shown to be similar for the GF-loaded group and the positive control 
(constructs were only cultured in endothelial media (EBM-20) supplemented with VEGF and 
PDGF) and was significantly higher than the pre-load group (Direct GF incorporation prior to 
cell seeding, equivalent to bolus injection), reaching approximately 190, 210 and 85 µm of 
infiltration depth in average, respectively (Fig. 12C,F). In conclusion, the PCL/collagen-
Heprasil loaded hybrid scaffolds were shown to be able to recapitulate the primitive capillary 
network required for vascularized TECs, by initiating a capillary network not only on the 
surface but also throughout the scaffolds. However, the previous release profiles and 
bioactivity results suggest that this system may be effective only in the first days of cell 
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culture, rather than providing a continuous effectiveness over several weeks of culture. The 
morphogenic and chemotactic actions provided by this initial kick-start may be responsible 
for initial migration of cells in the constructs, triggering subsequent formation of endothelial 
network [48].  
Electrospraying of cells 
Electrospraying has also been employed to produce cellularized constructs by 
simultaneous electrospraying of smooth muscle cells (SMCs) and electrospinning of PEUU 
nanofibers [134]. Such co-processing allowed the integration of cells into the smallest pores 
of the electrospun scaffold as it was constructed, providing a large numbers of cells which 
infiltrated throughout the bulk after a few days of perfusion culture, which had spread within 
the scaffold. Importantly, there was no significant decrease in cell viability and 
electrosprayed SMCs spread and proliferated at a similar rate than the control unprocessed 
SMCs while cells sprayed from a bottle without voltage did not. The sprayed cell 
suspensions were supplemented with 3 wt% bovine skin gelatin for increasing viscosity and 
maximizing viability by protecting cells from mechanical and chemical stresses, since the 
physical forces of the pressurized spray in combination with the exposure of cells to 
processing solvents initially caused a significant reduction in SMC viability. Mechanical 
integrity was disrupted because of gelation within the fiber network. Because viability and 
proliferation of electrosprayed cells were not affected, they were electrosprayed with media 
alone, maintaining the mechanical properties of the construct. These results underline the 
advantage of electrospraying over simple spraying and are consistent with literature stating 
that cells can survive exposure to high voltage [134]. Importantly, the SMC-integrated PEUU 
composites presented lower tensile strengths and higher breaking strains, which were 
explained by the cells disrupting the PEUU fiber network and replacing elastic PEUU volume 
with cellular volume. The authors still concluded that the measured properties were still more 
than sufficient for the SMC-integrated PEUU composites to serve as a support structure for 
soft tissue growth and mechanical training.  
Following these encouraging results, the same authors extended their process to the 
fabrication of small-diameter tubular conduits that possess mechanical properties similar to 
native blood vessels, after only a few days in culture (Fig. 12A) [143]. A 4.7 mm diameter 
mandrel was used in place of the previously employed 19 mm for sheets [134]. Interestingly 
they decreased the TTC distance from 5.0 to 4.5 cm and lowered the mandrel negative charge 
from -10 to -3 kV to obtain reproducible and defect free small-diameter tubular constructs. 
SMC integration was uniform radially and circumferentially within the conduits after initial 
static culture, while conduits were strong and flexible with mechanical properties that 
mimicked those of native arteries. Cultures of such cell-based scaffolds are recommended to 
be performed in spinner flasks or perfusion rather than static, since in both cases they led to 
much higher viable cells and enhanced spreading within the electrospun fibers [134, 143]. 
In 2008, mention of simultaneous electrospraying of chondrocytes and electrospinning of 
PCL was made in a review by Wu et al. [70]. They stated that confocal microscopy was used 
to visualize the living cells embedded in the fibers after being cultured in the cell media for a 
set time not mentioned. They also stated that the experimental results revealed that 80% of 
the cells were still viable after the electrohydrodynamic process, while no more information 
than this was provided (no description of materials or methods).  
Although the futility of the last study, electrospraying of cells with simultaneous 
electrospinning of a polymer matrix remains an efficient and rapid method for the production 
of tissue-engineered constructs. However, this is by no means a trivial and straight forward 
procedure and issues of sterility and time required to produce thicker scaffolds may 
potentially limit this application [133]. 
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Fig. 12.  (A) Schematic of the microintegration process of SMCs into PEUU fibers for small-
diameter blood vessel construct fabrication. A perpendicular nozzle configuration was 
utilized for electrospinning PEUU (6wt% in HFIP at 1.5mL/h) and electrospraying SMCs 
(7.5x10
-6 
SMCs/mL in medium at 0.1mL/min) onto a rotating small-diameter mandrel (4.7 
mm, 250 rpm) transversing on a linear stage (1.6 mm/s). The macroscale appearance of 
SMC microintegrated PEUU tubular constructs are illustrated after removal from the 
mandrel (bottom right hand corner) [143]. (B-F) 3D vascularization of GF-releasing hybrid 
scaffold of PCL/collagen fibers and HyA hydrogel [48]. (B) Schematic of the co-
electrospraying/electrospinning setup used for production of meshes, allowing simultaneous 
deposition of PCL/collagen fibers and HyA hydrogel. (C) Cellular infiltration measured by 
vWF section staining (Co-culture of HUVEC cells and LF) and endothelial network 
formation in meshes cultured in media supplemented with VEGF/PDGF (+ve control), 
meshed loaded with VEGF/PDGF in the Heprasil component during fabrication (200 ng/cm
2
 
each) (GF load), meshes loaded shortly prior to seeding (200 ng/cm
2
 each) (Pre-load) and 
meshes lacking VEGF/PDGF (-ve control). Scale bars are 50 µm. (D) Release of VEGF and 
PDGF from meshes studied in vitro via ELISA. (E) Bioactivity of the incorporated VEGF 
and PDGF by cell proliferation assessment. Percentage bioactivity was obtained through 
comparison with equal amount of fresh VEGF and PDGF as 100% values. Adapted from 
[48, 143] with permission. 2007, 2010 Elsevier Science Ltd. 
 
6. Conclusions 
 
The controlled and targeted delivery of therapeutic molecules is tantamount to the success 
of many medical treatments. With the development of superior treatment options for cancer, 
asthma and hormonal therapies there is a concomitant demand to encapsulate and release the 
active molecules in a safe, reproducible and effective manner.  
The technique of electrospraying has emerged as a promising technology to 
produce particles with entrapped therapeutic molecules which may be released as the particle 
degrades. The size and morphology of the particles produced are of paramount importance to 
enable batch-to-batch reproducibility and appropriate efficacy of the system. We have 
reviewed the many variables and interplays of the processing parameters which affect the 
production of microparticles and have highlighted the shortfalls associated with many current 
technologies. Importantly we have also highlighted the need to thoroughly assess and publish 
the encapsulation efficiencies, bioactivity and denaturation of the encapsulated biomolecules, 
both in vitro and in vivo. Only when all of these considerations are properly tackled can 
a delivery system for the use in targeted biomolecule delivery -  for example in tissue 
engineering, be properly realized and translated to the clinic. 
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